US20230420137A1 - Cancer Score for Assessment and Response Prediction from Biological Fluids - Google Patents
Cancer Score for Assessment and Response Prediction from Biological Fluids Download PDFInfo
- Publication number
- US20230420137A1 US20230420137A1 US18/465,868 US202318465868A US2023420137A1 US 20230420137 A1 US20230420137 A1 US 20230420137A1 US 202318465868 A US202318465868 A US 202318465868A US 2023420137 A1 US2023420137 A1 US 2023420137A1
- Authority
- US
- United States
- Prior art keywords
- dna
- cancer
- repair
- gene
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 275
- 201000011510 cancer Diseases 0.000 title claims abstract description 228
- 230000004044 response Effects 0.000 title description 17
- 239000013060 biological fluid Substances 0.000 title 1
- 230000033616 DNA repair Effects 0.000 claims abstract description 172
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 160
- 238000011282 treatment Methods 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 43
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 28
- 108020004414 DNA Proteins 0.000 claims description 176
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 81
- 230000035772 mutation Effects 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 32
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 27
- 108020004999 messenger RNA Proteins 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 108700026220 vif Genes Proteins 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 108091027963 non-coding RNA Proteins 0.000 claims description 12
- 102000042567 non-coding RNA Human genes 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 230000001973 epigenetic effect Effects 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims 2
- 238000004393 prognosis Methods 0.000 abstract description 27
- 206010061218 Inflammation Diseases 0.000 abstract description 17
- 230000004054 inflammatory process Effects 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 90
- 230000008439 repair process Effects 0.000 description 74
- 230000028617 response to DNA damage stimulus Effects 0.000 description 71
- -1 AMER11 Proteins 0.000 description 44
- 238000005215 recombination Methods 0.000 description 39
- 230000006798 recombination Effects 0.000 description 39
- 230000004543 DNA replication Effects 0.000 description 37
- 230000033607 mismatch repair Effects 0.000 description 36
- 230000004060 metabolic process Effects 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 238000012270 DNA recombination Methods 0.000 description 30
- 230000010076 replication Effects 0.000 description 29
- 238000013518 transcription Methods 0.000 description 28
- 230000035897 transcription Effects 0.000 description 28
- 108091092259 cell-free RNA Proteins 0.000 description 25
- 230000012361 double-strand break repair Effects 0.000 description 23
- 210000001124 body fluid Anatomy 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 18
- 230000006378 damage Effects 0.000 description 17
- 230000001419 dependent effect Effects 0.000 description 17
- 230000021121 meiosis Effects 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 230000033590 base-excision repair Effects 0.000 description 15
- 230000022131 cell cycle Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 102100037851 Replication factor C subunit 2 Human genes 0.000 description 13
- 230000006846 excision repair Effects 0.000 description 13
- 230000020520 nucleotide-excision repair Effects 0.000 description 12
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 11
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 11
- 108010027647 Replication Protein C Proteins 0.000 description 11
- 230000033228 biological regulation Effects 0.000 description 11
- 230000023852 carbohydrate metabolic process Effects 0.000 description 11
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 11
- 230000002950 deficient Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 10
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 10
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000012820 cell cycle checkpoint Effects 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000037425 regulation of transcription Effects 0.000 description 10
- 230000005778 DNA damage Effects 0.000 description 9
- 231100000277 DNA damage Toxicity 0.000 description 9
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000036365 BRCA1 Human genes 0.000 description 8
- 108700020463 BRCA1 Proteins 0.000 description 8
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 8
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 description 8
- 101000620730 Schizosaccharomyces pombe (strain 972 / ATCC 24843) DNA repair protein rhp51 Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108700020462 BRCA2 Proteins 0.000 description 7
- 230000012746 DNA damage checkpoint Effects 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 6
- 101150072950 BRCA1 gene Proteins 0.000 description 6
- 101150008921 Brca2 gene Proteins 0.000 description 6
- 102000003844 DNA helicases Human genes 0.000 description 6
- 108090000133 DNA helicases Proteins 0.000 description 6
- 108700010013 HMGB1 Proteins 0.000 description 6
- 101150021904 HMGB1 gene Proteins 0.000 description 6
- 102100037907 High mobility group protein B1 Human genes 0.000 description 6
- 101000981336 Homo sapiens Nibrin Proteins 0.000 description 6
- 102100024403 Nibrin Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000007851 telomere maintenance via telomerase Effects 0.000 description 6
- 102100031441 Cell cycle checkpoint protein RAD17 Human genes 0.000 description 5
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- 241000699802 Cricetulus griseus Species 0.000 description 5
- 230000008168 DNA dependent DNA replication Effects 0.000 description 5
- 102100031866 DNA excision repair protein ERCC-5 Human genes 0.000 description 5
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 5
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 description 5
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 description 5
- 201000004939 Fanconi anemia Diseases 0.000 description 5
- 102100026121 Flap endonuclease 1 Human genes 0.000 description 5
- 101001130422 Homo sapiens Cell cycle checkpoint protein RAD17 Proteins 0.000 description 5
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 5
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 description 5
- 101000615492 Homo sapiens Methyl-CpG-binding domain protein 4 Proteins 0.000 description 5
- 102100021290 Methyl-CpG-binding domain protein 4 Human genes 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000001195 RAD51 Human genes 0.000 description 5
- 108010068097 Rad51 Recombinase Proteins 0.000 description 5
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 5
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 230000006780 non-homologous end joining Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 102100035886 Adenine DNA glycosylase Human genes 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 208000010200 Cockayne syndrome Diseases 0.000 description 4
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 4
- 102100031868 DNA excision repair protein ERCC-8 Human genes 0.000 description 4
- 102100028849 DNA mismatch repair protein Mlh3 Human genes 0.000 description 4
- 102100037700 DNA mismatch repair protein Msh3 Human genes 0.000 description 4
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 4
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 description 4
- 201000000106 Fanconi anemia complementation group A Diseases 0.000 description 4
- 102100034555 Fanconi anemia group G protein Human genes 0.000 description 4
- 108090000652 Flap endonucleases Proteins 0.000 description 4
- 108050007570 GTP-binding protein Rad Proteins 0.000 description 4
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 4
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 4
- 101000580659 Homo sapiens ATP-dependent DNA helicase Q1 Proteins 0.000 description 4
- 101001000351 Homo sapiens Adenine DNA glycosylase Proteins 0.000 description 4
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 4
- 101000920778 Homo sapiens DNA excision repair protein ERCC-8 Proteins 0.000 description 4
- 101000577867 Homo sapiens DNA mismatch repair protein Mlh3 Proteins 0.000 description 4
- 101001027762 Homo sapiens DNA mismatch repair protein Msh3 Proteins 0.000 description 4
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 4
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 4
- 101000968663 Homo sapiens MutS protein homolog 5 Proteins 0.000 description 4
- 102000015335 Ku Autoantigen Human genes 0.000 description 4
- 108010025026 Ku Autoantigen Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 4
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 description 4
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 102100021156 MutS protein homolog 5 Human genes 0.000 description 4
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 4
- 101150006234 RAD52 gene Proteins 0.000 description 4
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 4
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 4
- 206010048218 Xeroderma Diseases 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000022984 regulation of mitotic recombination Effects 0.000 description 4
- 230000013707 sensory perception of sound Effects 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020001738 DNA Glycosylase Proteins 0.000 description 3
- 102100033697 DNA cross-link repair 1A protein Human genes 0.000 description 3
- 102000028381 DNA glycosylase Human genes 0.000 description 3
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 3
- 102100022302 DNA polymerase beta Human genes 0.000 description 3
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 3
- 102100035474 DNA polymerase kappa Human genes 0.000 description 3
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 3
- 102100022474 DNA repair protein complementing XP-A cells Human genes 0.000 description 3
- 102100035619 DNA-(apurinic or apyrimidinic site) lyase Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 102100031593 DNA-directed RNA polymerase I subunit RPA1 Human genes 0.000 description 3
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 101000620746 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) DNA repair and recombination protein radC Proteins 0.000 description 3
- 102100023688 Eotaxin Human genes 0.000 description 3
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 description 3
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 description 3
- 201000000143 Fanconi anemia complementation group E Diseases 0.000 description 3
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 102100022128 High mobility group protein B2 Human genes 0.000 description 3
- 102100022130 High mobility group protein B3 Human genes 0.000 description 3
- 101000743497 Homo sapiens ATP-dependent DNA helicase Q5 Proteins 0.000 description 3
- 101000871548 Homo sapiens DNA cross-link repair 1A protein Proteins 0.000 description 3
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 3
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 3
- 101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 description 3
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 3
- 101001137256 Homo sapiens DNA-(apurinic or apyrimidinic site) lyase Proteins 0.000 description 3
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 description 3
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 description 3
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 3
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 3
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 description 3
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108700019589 MRE11 Homologue Proteins 0.000 description 3
- 101000620741 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) DNA repair and recombination protein rhm52 Proteins 0.000 description 3
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 3
- 101000620743 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) DNA repair and recombination protein mus-11 Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 3
- 102100020779 UV excision repair protein RAD23 homolog B Human genes 0.000 description 3
- 102000002258 X-ray Repair Cross Complementing Protein 1 Human genes 0.000 description 3
- 108010000443 X-ray Repair Cross Complementing Protein 1 Proteins 0.000 description 3
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000032969 meiotic prophase I Effects 0.000 description 3
- 230000022779 meiotic prophase II Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 101150071637 mre11 gene Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000003068 pathway analysis Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 230000033863 telomere maintenance Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000033587 transcription-coupled nucleotide-excision repair Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- KIAPWMKFHIKQOZ-UHFFFAOYSA-N 2-[[(4-fluorophenyl)-oxomethyl]amino]benzoic acid methyl ester Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1 KIAPWMKFHIKQOZ-UHFFFAOYSA-N 0.000 description 2
- UBKVUFQGVWHZIR-UHFFFAOYSA-N 8-oxoguanine Chemical compound O=C1NC(N)=NC2=NC(=O)N=C21 UBKVUFQGVWHZIR-UHFFFAOYSA-N 0.000 description 2
- 102100027447 ATP-dependent DNA helicase Q1 Human genes 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000005692 Bloom Syndrome Diseases 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102100036883 Cyclin-H Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 102000012698 DDB1 Human genes 0.000 description 2
- 102000010567 DNA Polymerase II Human genes 0.000 description 2
- 108010063113 DNA Polymerase II Proteins 0.000 description 2
- 102000007528 DNA Polymerase III Human genes 0.000 description 2
- 108010071146 DNA Polymerase III Proteins 0.000 description 2
- 230000018706 DNA damage response, signal transduction resulting in induction of apoptosis Effects 0.000 description 2
- 102100021122 DNA damage-binding protein 2 Human genes 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- 108010035476 DNA excision repair protein ERCC-5 Proteins 0.000 description 2
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 description 2
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 2
- 102100035472 DNA polymerase iota Human genes 0.000 description 2
- 102100028216 DNA polymerase zeta catalytic subunit Human genes 0.000 description 2
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 2
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 description 2
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 2
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 description 2
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 2
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 description 2
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 2
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 2
- 102100037377 DNA-(apurinic or apyrimidinic site) endonuclease 2 Human genes 0.000 description 2
- 102100039851 DNA-directed RNA polymerases I and III subunit RPAC1 Human genes 0.000 description 2
- 101100226017 Dictyostelium discoideum repD gene Proteins 0.000 description 2
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 2
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 2
- 101150105460 ERCC2 gene Proteins 0.000 description 2
- 101710180995 Endonuclease 1 Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 102100029075 Exonuclease 1 Human genes 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 description 2
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 description 2
- 102100039701 G antigen 2B/2C Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000580577 Homo sapiens ATP-dependent DNA helicase Q4 Proteins 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 description 2
- 101001041466 Homo sapiens DNA damage-binding protein 2 Proteins 0.000 description 2
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 description 2
- 101000863770 Homo sapiens DNA ligase 1 Proteins 0.000 description 2
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 2
- 101000927810 Homo sapiens DNA ligase 4 Proteins 0.000 description 2
- 101000902539 Homo sapiens DNA polymerase beta Proteins 0.000 description 2
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 description 2
- 101000579381 Homo sapiens DNA polymerase zeta catalytic subunit Proteins 0.000 description 2
- 101000770953 Homo sapiens DNA repair endonuclease XPF Proteins 0.000 description 2
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 description 2
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 2
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 2
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 2
- 101000806823 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease 2 Proteins 0.000 description 2
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 2
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 description 2
- 101000970385 Homo sapiens Endonuclease III-like protein 1 Proteins 0.000 description 2
- 101000886134 Homo sapiens G antigen 2B/2C Proteins 0.000 description 2
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 2
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 2
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 2
- 101000583811 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2B Proteins 0.000 description 2
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 2
- 101000998855 Homo sapiens Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 2
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 description 2
- 101001094809 Homo sapiens Polynucleotide 5'-hydroxyl-kinase Proteins 0.000 description 2
- 101000933601 Homo sapiens Protein BTG1 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101001096365 Homo sapiens Replication factor C subunit 2 Proteins 0.000 description 2
- 101001096355 Homo sapiens Replication factor C subunit 3 Proteins 0.000 description 2
- 101000582412 Homo sapiens Replication factor C subunit 5 Proteins 0.000 description 2
- 101000709305 Homo sapiens Replication protein A 14 kDa subunit Proteins 0.000 description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
- 101000664956 Homo sapiens Single-strand selective monofunctional uracil DNA glycosylase Proteins 0.000 description 2
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 2
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 2
- 101000735431 Homo sapiens Terminal nucleotidyltransferase 4A Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 2
- 101000807337 Homo sapiens Ubiquitin-conjugating enzyme E2 B Proteins 0.000 description 2
- 101000804921 Homo sapiens X-ray repair cross-complementing protein 5 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 229910015837 MSH2 Inorganic materials 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 2
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
- 102100027257 Melanoma-associated antigen D4 Human genes 0.000 description 2
- 101000669895 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Replication factor A Proteins 0.000 description 2
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108091033773 MiR-155 Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 102100030955 Mitotic spindle assembly checkpoint protein MAD2B Human genes 0.000 description 2
- 102000010645 MutS Proteins Human genes 0.000 description 2
- 108010038272 MutS Proteins Proteins 0.000 description 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 2
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 description 2
- 108010064209 Phosphoribosylglycinamide formyltransferase Proteins 0.000 description 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 2
- 102100035460 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 101710132457 Protein A1 Proteins 0.000 description 2
- 102100026036 Protein BTG1 Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 230000021839 RNA stabilization Effects 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102100037855 Replication factor C subunit 3 Human genes 0.000 description 2
- 102100030541 Replication factor C subunit 5 Human genes 0.000 description 2
- 102100034372 Replication protein A 14 kDa subunit Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 102100038661 Single-strand selective monofunctional uracil DNA glycosylase Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 2
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102100020845 UV excision repair protein RAD23 homolog A Human genes 0.000 description 2
- 101710204645 UV excision repair protein RAD23 homolog B Proteins 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 2
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 2
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 2
- 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 description 2
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 2
- 101710160987 Uracil-DNA glycosylase Proteins 0.000 description 2
- 101150045640 VWF gene Proteins 0.000 description 2
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 2
- 108700031763 Xeroderma Pigmentosum Group D Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091006374 cAMP receptor proteins Proteins 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000009134 cell regulation Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000011855 chromosome organization Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 101150077768 ddb1 gene Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 2
- 108091007431 miR-29 Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000032929 negative regulation of cell cycle Effects 0.000 description 2
- 230000031918 negative regulation of centriole replication Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 230000015265 positive regulation of DNA ligation Effects 0.000 description 2
- 230000032029 positive regulation of DNA repair Effects 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000033586 regulation of DNA repair Effects 0.000 description 2
- 230000025915 regulation of apoptotic process Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000028413 regulation of transcription from RNA polymerase III promoter Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 230000033443 single strand break repair Effects 0.000 description 2
- 230000018381 sister chromatid cohesion Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000008549 xeroderma pigmentosum group E Diseases 0.000 description 2
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 description 2
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LMXHFXAFDMNKIM-UHFFFAOYSA-N 1-(2-hydroxyethyl)-5-nitropyrrole-2-carbonitrile Chemical compound OCCN1C(C#N)=CC=C1[N+]([O-])=O LMXHFXAFDMNKIM-UHFFFAOYSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 101710111653 2-methylisocitrate lyase Proteins 0.000 description 1
- 102100039082 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 Human genes 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 102100022032 39S ribosomal protein L1, mitochondrial Human genes 0.000 description 1
- 102100020971 39S ribosomal protein L10, mitochondrial Human genes 0.000 description 1
- 102100020966 39S ribosomal protein L11, mitochondrial Human genes 0.000 description 1
- 102100026163 39S ribosomal protein L12, mitochondrial Human genes 0.000 description 1
- 102100026146 39S ribosomal protein L13, mitochondrial Human genes 0.000 description 1
- 102100026433 39S ribosomal protein L14, mitochondrial Human genes 0.000 description 1
- 102100040272 39S ribosomal protein L9, mitochondrial Human genes 0.000 description 1
- 102100025915 5' exonuclease Apollo Human genes 0.000 description 1
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 1
- 102100035916 60S ribosomal protein L11 Human genes 0.000 description 1
- 102100031854 60S ribosomal protein L14 Human genes 0.000 description 1
- 102100026750 60S ribosomal protein L5 Human genes 0.000 description 1
- 102100035931 60S ribosomal protein L8 Human genes 0.000 description 1
- 102100041029 60S ribosomal protein L9 Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100038776 ADP-ribosylation factor-related protein 1 Human genes 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 102100022984 AP-2 complex subunit alpha-1 Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 description 1
- 102100034571 AT-rich interactive domain-containing protein 1B Human genes 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 102100023619 ATP synthase F(0) complex subunit B1, mitochondrial Human genes 0.000 description 1
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 1
- 102100027452 ATP-dependent DNA helicase Q4 Human genes 0.000 description 1
- 101150020330 ATRX gene Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100021636 Actin-related protein 2/3 complex subunit 2 Human genes 0.000 description 1
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 102100024439 Adhesion G protein-coupled receptor A2 Human genes 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000002226 Alkyl and Aryl Transferases Human genes 0.000 description 1
- 108010014722 Alkyl and Aryl Transferases Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100040410 Alpha-methylacyl-CoA racemase Human genes 0.000 description 1
- 108010044434 Alpha-methylacyl-CoA racemase Proteins 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 101100510324 Aplysia californica PRKC1 gene Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100024044 Aprataxin Human genes 0.000 description 1
- 101100481794 Arabidopsis thaliana TOC34 gene Proteins 0.000 description 1
- 102100028820 Aspartate-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102100027710 Astacin-like metalloendopeptidase Human genes 0.000 description 1
- 101710166179 Astacin-like metalloendopeptidase Proteins 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 102100035682 Axin-1 Human genes 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100035565 B melanoma antigen 2 Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100022983 B-cell lymphoma/leukemia 11B Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 102100021247 BCL-6 corepressor Human genes 0.000 description 1
- 102100021256 BCL-6 corepressor-like protein 1 Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 102100027161 BRCA2-interacting transcriptional repressor EMSY Human genes 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 102100035645 Biogenesis of lysosome-related organelles complex 1 subunit 1 Human genes 0.000 description 1
- 102100035631 Bloom syndrome protein Human genes 0.000 description 1
- 108091009167 Bloom syndrome protein Proteins 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 description 1
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 description 1
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025905 C-Jun-amino-terminal kinase-interacting protein 4 Human genes 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 102100039435 C-X-C motif chemokine 17 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 102100035893 CD151 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 102100030933 CDK-activating kinase assembly factor MAT1 Human genes 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- 108091058556 CTAG1B Proteins 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 101000743841 Caenorhabditis elegans Ras-related protein Rab-10 Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 101100262777 Caenorhabditis elegans umps-1 gene Proteins 0.000 description 1
- 102100029801 Calcium-transporting ATPase type 2C member 1 Human genes 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 102100025172 Calpain-1 catalytic subunit Human genes 0.000 description 1
- 102100025933 Cancer-associated gene 1 protein Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 102100028003 Catenin alpha-1 Human genes 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 102100025175 Cellular communication network factor 6 Human genes 0.000 description 1
- 102100037631 Centrin-2 Human genes 0.000 description 1
- 102100028487 Checkpoint protein HUS1 Human genes 0.000 description 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 1
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 description 1
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 1
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 1
- 102100029375 Crk-like protein Human genes 0.000 description 1
- 102100028908 Cullin-3 Human genes 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 1
- 102100023578 Cyclic AMP-dependent transcription factor ATF-7 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 description 1
- 102000009503 Cyclin-Dependent Kinase Inhibitor p18 Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 102100026891 Cystatin-B Human genes 0.000 description 1
- 102100030115 Cysteine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100041024 Cytochrome c oxidase assembly protein COX11, mitochondrial Human genes 0.000 description 1
- 102100024638 Cytochrome c oxidase subunit 5B, mitochondrial Human genes 0.000 description 1
- 102100039259 Cytochrome c oxidase subunit 8A, mitochondrial Human genes 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101150077031 DAXX gene Proteins 0.000 description 1
- 102100029816 DEP domain-containing mTOR-interacting protein Human genes 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 108010001132 DNA Polymerase beta Proteins 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 230000011479 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator Effects 0.000 description 1
- 230000028679 DNA dealkylation Effects 0.000 description 1
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 description 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 102100024823 DNA polymerase delta subunit 2 Human genes 0.000 description 1
- 102100020782 DNA polymerase delta subunit 3 Human genes 0.000 description 1
- 102100029903 DNA polymerase epsilon catalytic subunit A Human genes 0.000 description 1
- 102100029910 DNA polymerase epsilon subunit 2 Human genes 0.000 description 1
- 108010025600 DNA polymerase iota Proteins 0.000 description 1
- 102100036951 DNA polymerase subunit gamma-1 Human genes 0.000 description 1
- 102100029766 DNA polymerase theta Human genes 0.000 description 1
- 102100034490 DNA repair and recombination protein RAD54B Human genes 0.000 description 1
- 102100028285 DNA repair protein REV1 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 description 1
- 101710109420 DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 1
- 102100039303 DNA-directed RNA polymerase II subunit RPB2 Human genes 0.000 description 1
- 102100039301 DNA-directed RNA polymerase II subunit RPB3 Human genes 0.000 description 1
- 102100032260 DNA-directed RNA polymerase II subunit RPB4 Human genes 0.000 description 1
- 102100027480 DNA-directed RNA polymerase III subunit RPC3 Human genes 0.000 description 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
- 102100036462 Delta-like protein 1 Human genes 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 241001669680 Dormitator maculatus Species 0.000 description 1
- 101100482131 Drosophila melanogaster Trf4-2 gene Proteins 0.000 description 1
- 101100483248 Drosophila melanogaster gkt gene Proteins 0.000 description 1
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 101150113929 EBNA2 gene Proteins 0.000 description 1
- 108700015856 ELAV-Like Protein 1 Proteins 0.000 description 1
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 101150073167 Eif1 gene Proteins 0.000 description 1
- 101150082742 Eif1b gene Proteins 0.000 description 1
- 101150011861 Elavl1 gene Proteins 0.000 description 1
- 102100030209 Elongin-B Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100028778 Endonuclease 8-like 1 Human genes 0.000 description 1
- 102100021710 Endonuclease III-like protein 1 Human genes 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 1
- 102100030770 Enhancer of rudimentary homolog Human genes 0.000 description 1
- 101150025643 Epha5 gene Proteins 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 1
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102100029775 Eukaryotic translation initiation factor 1 Human genes 0.000 description 1
- 102100029774 Eukaryotic translation initiation factor 1b Human genes 0.000 description 1
- 102100027327 Eukaryotic translation initiation factor 2 subunit 2 Human genes 0.000 description 1
- 102100034169 Eukaryotic translation initiation factor 2-alpha kinase 1 Human genes 0.000 description 1
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 1
- 102100038045 Eukaryotic translation initiation factor 2A Human genes 0.000 description 1
- 102100034295 Eukaryotic translation initiation factor 3 subunit A Human genes 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 description 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 description 1
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 description 1
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 description 1
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 description 1
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 description 1
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 description 1
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 description 1
- 102100040306 Fanconi anemia group D2 protein Human genes 0.000 description 1
- 102100034553 Fanconi anemia group J protein Human genes 0.000 description 1
- 102100036118 Far upstream element-binding protein 1 Human genes 0.000 description 1
- 101100058548 Felis catus BMI1 gene Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100035292 Fibroblast growth factor 14 Human genes 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102100021066 Fibroblast growth factor receptor substrate 2 Human genes 0.000 description 1
- 101710088570 Flagellar hook-associated protein 1 Proteins 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- 102100027909 Folliculin Human genes 0.000 description 1
- 108010010285 Forkhead Box Protein L2 Proteins 0.000 description 1
- 102100035137 Forkhead box protein L2 Human genes 0.000 description 1
- 102100028122 Forkhead box protein P1 Human genes 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 description 1
- 102100022277 Fructose-bisphosphate aldolase A Human genes 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102100039714 G antigen 10 Human genes 0.000 description 1
- 102100036304 G antigen 12B/C/D/E Human genes 0.000 description 1
- 102100036295 G antigen 12F Human genes 0.000 description 1
- 102100021019 G antigen 12J Human genes 0.000 description 1
- 102100039712 G antigen 13 Human genes 0.000 description 1
- 102100039709 G antigen 2A Human genes 0.000 description 1
- 102100040003 G antigen 2D Human genes 0.000 description 1
- 102100039700 G antigen 2E Human genes 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 102000017691 GABRA6 Human genes 0.000 description 1
- 102000019448 GART Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 description 1
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100038308 General transcription factor IIH subunit 1 Human genes 0.000 description 1
- 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 description 1
- 102100032862 General transcription factor IIH subunit 4 Human genes 0.000 description 1
- 102100028650 Glucose-induced degradation protein 4 homolog Human genes 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
- 102100036589 Glycine-tRNA ligase Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 102100036703 Guanine nucleotide-binding protein subunit alpha-13 Human genes 0.000 description 1
- 108091059596 H3F3A Proteins 0.000 description 1
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 102100028765 Heat shock 70 kDa protein 4 Human genes 0.000 description 1
- 102100027529 Heat shock factor-binding protein 1 Human genes 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102100033985 Heterogeneous nuclear ribonucleoprotein D0 Human genes 0.000 description 1
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101800001941 Hippocampal cholinergic neurostimulating peptide Proteins 0.000 description 1
- 102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102100023917 Histone H1.10 Human genes 0.000 description 1
- 102100039236 Histone H3.3 Human genes 0.000 description 1
- 102100033071 Histone acetyltransferase KAT6A Human genes 0.000 description 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 description 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 102100029239 Histone-lysine N-methyltransferase, H3 lysine-36 specific Human genes 0.000 description 1
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 description 1
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 1
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 description 1
- 101000744065 Homo sapiens 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 Proteins 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101001107443 Homo sapiens 39S ribosomal protein L1, mitochondrial Proteins 0.000 description 1
- 101000854440 Homo sapiens 39S ribosomal protein L10, mitochondrial Proteins 0.000 description 1
- 101000854451 Homo sapiens 39S ribosomal protein L11, mitochondrial Proteins 0.000 description 1
- 101000691538 Homo sapiens 39S ribosomal protein L12, mitochondrial Proteins 0.000 description 1
- 101000691550 Homo sapiens 39S ribosomal protein L13, mitochondrial Proteins 0.000 description 1
- 101000692875 Homo sapiens 39S ribosomal protein L14, mitochondrial Proteins 0.000 description 1
- 101001104245 Homo sapiens 39S ribosomal protein L9, mitochondrial Proteins 0.000 description 1
- 101000720953 Homo sapiens 5' exonuclease Apollo Proteins 0.000 description 1
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 description 1
- 101001073740 Homo sapiens 60S ribosomal protein L11 Proteins 0.000 description 1
- 101000704267 Homo sapiens 60S ribosomal protein L14 Proteins 0.000 description 1
- 101001117935 Homo sapiens 60S ribosomal protein L15 Proteins 0.000 description 1
- 101000691083 Homo sapiens 60S ribosomal protein L5 Proteins 0.000 description 1
- 101000853659 Homo sapiens 60S ribosomal protein L8 Proteins 0.000 description 1
- 101000672886 Homo sapiens 60S ribosomal protein L9 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000809413 Homo sapiens ADP-ribosylation factor-related protein 1 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000757299 Homo sapiens AP-2 complex subunit alpha-1 Proteins 0.000 description 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 description 1
- 101000924255 Homo sapiens AT-rich interactive domain-containing protein 1B Proteins 0.000 description 1
- 101000905623 Homo sapiens ATP synthase F(0) complex subunit B1, mitochondrial Proteins 0.000 description 1
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000754220 Homo sapiens Actin-related protein 2/3 complex subunit 2 Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000833358 Homo sapiens Adhesion G protein-coupled receptor A2 Proteins 0.000 description 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000780137 Homo sapiens Annexin A6 Proteins 0.000 description 1
- 101000757586 Homo sapiens Aprataxin Proteins 0.000 description 1
- 101000833314 Homo sapiens Arf-GAP domain and FG repeat-containing protein 1 Proteins 0.000 description 1
- 101000696909 Homo sapiens Aspartate-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101000874566 Homo sapiens Axin-1 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000874318 Homo sapiens B melanoma antigen 2 Proteins 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000894688 Homo sapiens BCL-6 corepressor-like protein 1 Proteins 0.000 description 1
- 101100165236 Homo sapiens BCOR gene Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101001057996 Homo sapiens BRCA2-interacting transcriptional repressor EMSY Proteins 0.000 description 1
- 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
- 101000803232 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 1 Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000934858 Homo sapiens Breast cancer type 2 susceptibility protein Proteins 0.000 description 1
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 description 1
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101001076862 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 4 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101000728145 Homo sapiens Calcium-transporting ATPase type 2C member 1 Proteins 0.000 description 1
- 101000898052 Homo sapiens Calnexin Proteins 0.000 description 1
- 101000934069 Homo sapiens Calpain-1 catalytic subunit Proteins 0.000 description 1
- 101000933825 Homo sapiens Cancer-associated gene 1 protein Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 description 1
- 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000934310 Homo sapiens Cellular communication network factor 6 Proteins 0.000 description 1
- 101000880516 Homo sapiens Centrin-2 Proteins 0.000 description 1
- 101000737602 Homo sapiens Ceramide synthase 1 Proteins 0.000 description 1
- 101000839968 Homo sapiens Checkpoint protein HUS1 Proteins 0.000 description 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000883749 Homo sapiens Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 description 1
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 description 1
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 description 1
- 101000916238 Homo sapiens Cullin-3 Proteins 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 1
- 101000905723 Homo sapiens Cyclic AMP-dependent transcription factor ATF-7 Proteins 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 description 1
- 101000586290 Homo sapiens Cysteine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000748842 Homo sapiens Cytochrome c oxidase assembly protein COX11, mitochondrial Proteins 0.000 description 1
- 101000908835 Homo sapiens Cytochrome c oxidase subunit 5B, mitochondrial Proteins 0.000 description 1
- 101000745956 Homo sapiens Cytochrome c oxidase subunit 8A, mitochondrial Proteins 0.000 description 1
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000865183 Homo sapiens DEP domain-containing mTOR-interacting protein Proteins 0.000 description 1
- 101000920784 Homo sapiens DNA excision repair protein ERCC-5 Proteins 0.000 description 1
- 101000909189 Homo sapiens DNA polymerase delta subunit 2 Proteins 0.000 description 1
- 101000932004 Homo sapiens DNA polymerase delta subunit 3 Proteins 0.000 description 1
- 101000932009 Homo sapiens DNA polymerase delta subunit 4 Proteins 0.000 description 1
- 101000864180 Homo sapiens DNA polymerase epsilon catalytic subunit A Proteins 0.000 description 1
- 101000864190 Homo sapiens DNA polymerase epsilon subunit 2 Proteins 0.000 description 1
- 101000864175 Homo sapiens DNA polymerase epsilon subunit 3 Proteins 0.000 description 1
- 101001094607 Homo sapiens DNA polymerase eta Proteins 0.000 description 1
- 101001094672 Homo sapiens DNA polymerase iota Proteins 0.000 description 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 description 1
- 101000712511 Homo sapiens DNA repair and recombination protein RAD54-like Proteins 0.000 description 1
- 101001132263 Homo sapiens DNA repair and recombination protein RAD54B Proteins 0.000 description 1
- 101001132307 Homo sapiens DNA repair protein RAD51 homolog 2 Proteins 0.000 description 1
- 101000618531 Homo sapiens DNA repair protein complementing XP-A cells Proteins 0.000 description 1
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 1
- 101000865099 Homo sapiens DNA-directed DNA/RNA polymerase mu Proteins 0.000 description 1
- 101001088155 Homo sapiens DNA-directed RNA polymerase I subunit RPA49 Proteins 0.000 description 1
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 1
- 101000669831 Homo sapiens DNA-directed RNA polymerase II subunit RPB2 Proteins 0.000 description 1
- 101000669859 Homo sapiens DNA-directed RNA polymerase II subunit RPB3 Proteins 0.000 description 1
- 101001088177 Homo sapiens DNA-directed RNA polymerase II subunit RPB4 Proteins 0.000 description 1
- 101000650556 Homo sapiens DNA-directed RNA polymerase III subunit RPC3 Proteins 0.000 description 1
- 101000669166 Homo sapiens DNA-directed RNA polymerases I and III subunit RPAC1 Proteins 0.000 description 1
- 101000669171 Homo sapiens DNA-directed RNA polymerases I and III subunit RPAC2 Proteins 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101001130401 Homo sapiens E3 ubiquitin-protein ligase RAD18 Proteins 0.000 description 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101001011846 Homo sapiens Elongin-B Proteins 0.000 description 1
- 101001123824 Homo sapiens Endonuclease 8-like 1 Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 1
- 101000938759 Homo sapiens Enhancer of rudimentary homolog Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 description 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001020112 Homo sapiens Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 1
- 101001081893 Homo sapiens Eukaryotic translation initiation factor 2 subunit 2 Proteins 0.000 description 1
- 101000926530 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- 101000926508 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 description 1
- 101000810350 Homo sapiens Eukaryotic translation initiation factor 2A Proteins 0.000 description 1
- 101000959746 Homo sapiens Eukaryotic translation initiation factor 6 Proteins 0.000 description 1
- 101000918264 Homo sapiens Exonuclease 1 Proteins 0.000 description 1
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 description 1
- 101100479393 Homo sapiens FARSA gene Proteins 0.000 description 1
- 101000891683 Homo sapiens Fanconi anemia group D2 protein Proteins 0.000 description 1
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 description 1
- 101000930770 Homo sapiens Far upstream element-binding protein 1 Proteins 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101000878181 Homo sapiens Fibroblast growth factor 14 Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000818410 Homo sapiens Fibroblast growth factor receptor substrate 2 Proteins 0.000 description 1
- 101000913035 Homo sapiens Flap endonuclease 1 Proteins 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101001060703 Homo sapiens Folliculin Proteins 0.000 description 1
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 description 1
- 101000755879 Homo sapiens Fructose-bisphosphate aldolase A Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000886146 Homo sapiens G antigen 10 Proteins 0.000 description 1
- 101001074834 Homo sapiens G antigen 12B/C/D/E Proteins 0.000 description 1
- 101001074832 Homo sapiens G antigen 12F Proteins 0.000 description 1
- 101001075398 Homo sapiens G antigen 12J Proteins 0.000 description 1
- 101000886150 Homo sapiens G antigen 13 Proteins 0.000 description 1
- 101000886151 Homo sapiens G antigen 2A Proteins 0.000 description 1
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 1
- 101000886133 Homo sapiens G antigen 2E Proteins 0.000 description 1
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001001400 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-6 Proteins 0.000 description 1
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101001058369 Homo sapiens Glucose-induced degradation protein 4 homolog Proteins 0.000 description 1
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 1
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 description 1
- 101001072481 Homo sapiens Guanine nucleotide-binding protein subunit alpha-13 Proteins 0.000 description 1
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 description 1
- 101001078692 Homo sapiens Heat shock 70 kDa protein 4 Proteins 0.000 description 1
- 101001080298 Homo sapiens Heat shock factor-binding protein 1 Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 1
- 101001017535 Homo sapiens Heterogeneous nuclear ribonucleoprotein D0 Proteins 0.000 description 1
- 101000838964 Homo sapiens Heterogeneous nuclear ribonucleoprotein K Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000905024 Homo sapiens Histone H1.10 Proteins 0.000 description 1
- 101000944179 Homo sapiens Histone acetyltransferase KAT6A Proteins 0.000 description 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 description 1
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 description 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000634050 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-36 specific Proteins 0.000 description 1
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 description 1
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 description 1
- 101001003233 Homo sapiens Immediate early response gene 2 protein Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101001053339 Homo sapiens Inositol polyphosphate 4-phosphatase type II Proteins 0.000 description 1
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101000875582 Homo sapiens Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101001008854 Homo sapiens Kelch-like protein 6 Proteins 0.000 description 1
- 101001008857 Homo sapiens Kelch-like protein 7 Proteins 0.000 description 1
- 101001020452 Homo sapiens LIM/homeobox protein Lhx3 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000619640 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 1 Proteins 0.000 description 1
- 101001038435 Homo sapiens Leucine-zipper-like transcriptional regulator 1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 description 1
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 1
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 description 1
- 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 description 1
- 101000977270 Homo sapiens MMS19 nucleotide excision repair protein homolog Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000614988 Homo sapiens Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 description 1
- 101000949825 Homo sapiens Meiotic recombination protein DMC1/LIM15 homolog Proteins 0.000 description 1
- 101000825217 Homo sapiens Meiotic recombination protein SPO11 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001005725 Homo sapiens Melanoma-associated antigen 10 Proteins 0.000 description 1
- 101001005717 Homo sapiens Melanoma-associated antigen 12 Proteins 0.000 description 1
- 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 1
- 101001005723 Homo sapiens Melanoma-associated antigen 8 Proteins 0.000 description 1
- 101001005724 Homo sapiens Melanoma-associated antigen 9 Proteins 0.000 description 1
- 101001036688 Homo sapiens Melanoma-associated antigen B1 Proteins 0.000 description 1
- 101001036673 Homo sapiens Melanoma-associated antigen B10 Proteins 0.000 description 1
- 101001036679 Homo sapiens Melanoma-associated antigen B16 Proteins 0.000 description 1
- 101001036682 Homo sapiens Melanoma-associated antigen B18 Proteins 0.000 description 1
- 101001036686 Homo sapiens Melanoma-associated antigen B2 Proteins 0.000 description 1
- 101001036692 Homo sapiens Melanoma-associated antigen B3 Proteins 0.000 description 1
- 101001036691 Homo sapiens Melanoma-associated antigen B4 Proteins 0.000 description 1
- 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 1
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 description 1
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
- 101001057158 Homo sapiens Melanoma-associated antigen D1 Proteins 0.000 description 1
- 101001057154 Homo sapiens Melanoma-associated antigen D2 Proteins 0.000 description 1
- 101001057137 Homo sapiens Melanoma-associated antigen E1 Proteins 0.000 description 1
- 101001057133 Homo sapiens Melanoma-associated antigen E2 Proteins 0.000 description 1
- 101001057132 Homo sapiens Melanoma-associated antigen F1 Proteins 0.000 description 1
- 101001057135 Homo sapiens Melanoma-associated antigen H1 Proteins 0.000 description 1
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 1
- 101000578932 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 1
- 101000582631 Homo sapiens Menin Proteins 0.000 description 1
- 101000954986 Homo sapiens Merlin Proteins 0.000 description 1
- 101001032848 Homo sapiens Metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 101000602479 Homo sapiens Methionine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 1
- 101000573451 Homo sapiens Msx2-interacting protein Proteins 0.000 description 1
- 101000968674 Homo sapiens MutS protein homolog 4 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001111244 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 Proteins 0.000 description 1
- 101000588247 Homo sapiens Nascent polypeptide-associated complex subunit alpha Proteins 0.000 description 1
- 101000981973 Homo sapiens Nascent polypeptide-associated complex subunit alpha, muscle-specific form Proteins 0.000 description 1
- 101000633520 Homo sapiens Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101001007909 Homo sapiens Nuclear pore complex protein Nup93 Proteins 0.000 description 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 description 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 description 1
- 101000610206 Homo sapiens Pappalysin-1 Proteins 0.000 description 1
- 101000945735 Homo sapiens Parafibromin Proteins 0.000 description 1
- 101001095231 Homo sapiens Peptidyl-prolyl cis-trans isomerase D Proteins 0.000 description 1
- 101001091191 Homo sapiens Peptidyl-prolyl cis-trans isomerase F, mitochondrial Proteins 0.000 description 1
- 101000741978 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Proteins 0.000 description 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101000721645 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 101001087352 Homo sapiens Poly(U)-binding-splicing factor PUF60 Proteins 0.000 description 1
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 1
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 1
- 101000647571 Homo sapiens Pre-mRNA-splicing factor SYF1 Proteins 0.000 description 1
- 101001116674 Homo sapiens Prefoldin subunit 2 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000881614 Homo sapiens Probable RNA-binding protein EIF1AD Proteins 0.000 description 1
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101001125574 Homo sapiens Prostasin Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 101000736929 Homo sapiens Proteasome subunit alpha type-1 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101001046894 Homo sapiens Protein HID1 Proteins 0.000 description 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 1
- 101000738907 Homo sapiens Protein PMS2CL Proteins 0.000 description 1
- 101000848498 Homo sapiens Protein POLR1D, isoform 2 Proteins 0.000 description 1
- 101000883014 Homo sapiens Protein capicua homolog Proteins 0.000 description 1
- 101001064096 Homo sapiens Protein disulfide-thiol oxidoreductase Proteins 0.000 description 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 description 1
- 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000824318 Homo sapiens Protocadherin Fat 1 Proteins 0.000 description 1
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 description 1
- 101001005721 Homo sapiens Putative melanoma-associated antigen 5P Proteins 0.000 description 1
- 101001002182 Homo sapiens Putative postmeiotic segregation increased 2-like protein 3 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 description 1
- 101000580092 Homo sapiens RNA-binding protein 10 Proteins 0.000 description 1
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000582404 Homo sapiens Replication factor C subunit 4 Proteins 0.000 description 1
- 101000709341 Homo sapiens Replication protein A 30 kDa subunit Proteins 0.000 description 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 1
- 101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 description 1
- 101000703463 Homo sapiens Rho GTPase-activating protein 35 Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000687474 Homo sapiens Rhombotin-1 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000587434 Homo sapiens Serine/arginine-rich splicing factor 3 Proteins 0.000 description 1
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000783404 Homo sapiens Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Proteins 0.000 description 1
- 101001099058 Homo sapiens Serine/threonine-protein phosphatase PGAM5, mitochondrial Proteins 0.000 description 1
- 101000595252 Homo sapiens Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Proteins 0.000 description 1
- 101001094647 Homo sapiens Serum paraoxonase/arylesterase 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000824954 Homo sapiens Sorting nexin-2 Proteins 0.000 description 1
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 description 1
- 101000881267 Homo sapiens Spectrin alpha chain, erythrocytic 1 Proteins 0.000 description 1
- 101000618135 Homo sapiens Sperm-associated antigen 1 Proteins 0.000 description 1
- 101000836980 Homo sapiens Sperm-associated antigen 11A Proteins 0.000 description 1
- 101000836978 Homo sapiens Sperm-associated antigen 11B Proteins 0.000 description 1
- 101000642345 Homo sapiens Sperm-associated antigen 16 protein Proteins 0.000 description 1
- 101000642433 Homo sapiens Sperm-associated antigen 17 Proteins 0.000 description 1
- 101000618138 Homo sapiens Sperm-associated antigen 4 protein Proteins 0.000 description 1
- 101000618133 Homo sapiens Sperm-associated antigen 5 Proteins 0.000 description 1
- 101000618139 Homo sapiens Sperm-associated antigen 6 Proteins 0.000 description 1
- 101000618110 Homo sapiens Sperm-associated antigen 7 Proteins 0.000 description 1
- 101000618112 Homo sapiens Sperm-associated antigen 8 Proteins 0.000 description 1
- 101000908580 Homo sapiens Spliceosome RNA helicase DDX39B Proteins 0.000 description 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 description 1
- 101000689224 Homo sapiens Src-like-adapter 2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- 101000628885 Homo sapiens Suppressor of fused homolog Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101100462828 Homo sapiens TENT4B gene Proteins 0.000 description 1
- 101000666429 Homo sapiens Terminal nucleotidyltransferase 5C Proteins 0.000 description 1
- 101000830950 Homo sapiens Three prime repair exonuclease 2 Proteins 0.000 description 1
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 1
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
- 101000796134 Homo sapiens Thymidine phosphorylase Proteins 0.000 description 1
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 101000933542 Homo sapiens Transcription factor BTF3 Proteins 0.000 description 1
- 101000895882 Homo sapiens Transcription factor E2F4 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 1
- 101001050297 Homo sapiens Transcription factor JunD Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- 101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101001057681 Homo sapiens Translation initiation factor eIF-2B subunit beta Proteins 0.000 description 1
- 101000925982 Homo sapiens Translation initiation factor eIF-2B subunit delta Proteins 0.000 description 1
- 101001049688 Homo sapiens Translation initiation factor eIF-2B subunit gamma Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 1
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101000717428 Homo sapiens UV excision repair protein RAD23 homolog A Proteins 0.000 description 1
- 101000717424 Homo sapiens UV excision repair protein RAD23 homolog B Proteins 0.000 description 1
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 1
- 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 1
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000807668 Homo sapiens Uracil-DNA glycosylase Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 101000814511 Homo sapiens X antigen family member 2 Proteins 0.000 description 1
- 101000814497 Homo sapiens X antigen family member 3 Proteins 0.000 description 1
- 101000814496 Homo sapiens X antigen family member 5 Proteins 0.000 description 1
- 101000804928 Homo sapiens X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 101000788773 Homo sapiens Zinc finger and BTB domain-containing protein 2 Proteins 0.000 description 1
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 description 1
- 101000785698 Homo sapiens Zinc finger protein 276 Proteins 0.000 description 1
- 101000723661 Homo sapiens Zinc finger protein 703 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 101001026573 Homo sapiens cAMP-dependent protein kinase type I-alpha regulatory subunit Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102100020702 Immediate early response gene 2 protein Human genes 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100027004 Inhibin beta A chain Human genes 0.000 description 1
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 1
- 102100024366 Inositol polyphosphate 4-phosphatase type II Human genes 0.000 description 1
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100039060 Interleukin enhancer-binding factor 2 Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 241000580063 Ipomopsis rubra Species 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 102100036015 Isoleucine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 108091007984 KARS Proteins 0.000 description 1
- 102100027789 Kelch-like protein 7 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 102100036106 LIM/homeobox protein Lhx3 Human genes 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100022170 Leucine-rich repeats and immunoglobulin-like domains protein 1 Human genes 0.000 description 1
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 1
- 102100040274 Leucine-zipper-like transcriptional regulator 1 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 1
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 1
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 description 1
- 102100035529 Lysine-tRNA ligase Human genes 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100028333 MAGE-like protein 2 Human genes 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102000017274 MDM4 Human genes 0.000 description 1
- 108050005300 MDM4 Proteins 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 1
- 102100023474 MMS19 nucleotide excision repair protein homolog Human genes 0.000 description 1
- 101150100766 MUS81 gene Proteins 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100021070 Mediator of RNA polymerase II transcription subunit 12 Human genes 0.000 description 1
- 102100035285 Meiotic recombination protein DMC1/LIM15 homolog Human genes 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102100025049 Melanoma-associated antigen 10 Human genes 0.000 description 1
- 102100025084 Melanoma-associated antigen 12 Human genes 0.000 description 1
- 102100025081 Melanoma-associated antigen 2 Human genes 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 1
- 102100025076 Melanoma-associated antigen 8 Human genes 0.000 description 1
- 102100025079 Melanoma-associated antigen 9 Human genes 0.000 description 1
- 102100039477 Melanoma-associated antigen B1 Human genes 0.000 description 1
- 102100039482 Melanoma-associated antigen B10 Human genes 0.000 description 1
- 102100039481 Melanoma-associated antigen B16 Human genes 0.000 description 1
- 102100039478 Melanoma-associated antigen B18 Human genes 0.000 description 1
- 102100039479 Melanoma-associated antigen B2 Human genes 0.000 description 1
- 102100039473 Melanoma-associated antigen B3 Human genes 0.000 description 1
- 102100039476 Melanoma-associated antigen B4 Human genes 0.000 description 1
- 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 1
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 description 1
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 1
- 102100027247 Melanoma-associated antigen D1 Human genes 0.000 description 1
- 102100027251 Melanoma-associated antigen D2 Human genes 0.000 description 1
- 102100027255 Melanoma-associated antigen E2 Human genes 0.000 description 1
- 102100027258 Melanoma-associated antigen F1 Human genes 0.000 description 1
- 102100027256 Melanoma-associated antigen H1 Human genes 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 1
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 102100037106 Merlin Human genes 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 102100030157 Microphthalmia-associated transcription factor Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100026285 Msx2-interacting protein Human genes 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 description 1
- 102100021157 MutS protein homolog 4 Human genes 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 102100023950 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 Human genes 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102100026779 Nascent polypeptide-associated complex subunit alpha, muscle-specific form Human genes 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 102000001756 Notch2 Receptor Human genes 0.000 description 1
- 108010029751 Notch2 Receptor Proteins 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108700031302 Nuclear Factor 45 Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102100027585 Nuclear pore complex protein Nup93 Human genes 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 102100040156 Pappalysin-1 Human genes 0.000 description 1
- 102100034743 Parafibromin Human genes 0.000 description 1
- 102100040884 Partner and localizer of BRCA2 Human genes 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 102100037827 Peptidyl-prolyl cis-trans isomerase D Human genes 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- 102100035215 Phenylalanine-tRNA ligase alpha subunit Human genes 0.000 description 1
- 102100028489 Phosphatidylethanolamine-binding protein 1 Human genes 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 102100038633 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Human genes 0.000 description 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 1
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100025059 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta Human genes 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 101710118150 Podoplanin Proteins 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 102100033008 Poly(U)-binding-splicing factor PUF60 Human genes 0.000 description 1
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 1
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 1
- 102100024168 Polymerase delta-interacting protein 2 Human genes 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 102100025391 Pre-mRNA-splicing factor SYF1 Human genes 0.000 description 1
- 102100024920 Prefoldin subunit 2 Human genes 0.000 description 1
- 102100037234 Probable RNA-binding protein EIF1AD Human genes 0.000 description 1
- 102100025498 Proepiregulin Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 102100036042 Proteasome subunit alpha type-1 Human genes 0.000 description 1
- 101710132455 Protein A2 Proteins 0.000 description 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
- 102100030128 Protein L-Myc Human genes 0.000 description 1
- 102100037481 Protein PMS2CL Human genes 0.000 description 1
- 102100034616 Protein POLR1D, isoform 2 Human genes 0.000 description 1
- 102100038777 Protein capicua homolog Human genes 0.000 description 1
- 102100030728 Protein disulfide-thiol oxidoreductase Human genes 0.000 description 1
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 1
- 102100037516 Protein polybromo-1 Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 102100022095 Protocadherin Fat 1 Human genes 0.000 description 1
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 description 1
- 102100025078 Putative melanoma-associated antigen 5P Human genes 0.000 description 1
- 102100020956 Putative postmeiotic segregation increased 2-like protein 3 Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 102000001170 RAD18 Human genes 0.000 description 1
- 101710018890 RAD51B Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 102100027514 RNA-binding protein 10 Human genes 0.000 description 1
- 108090000740 RNA-binding protein EWS Proteins 0.000 description 1
- 102000004229 RNA-binding protein EWS Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 101150057233 RPL23A gene Proteins 0.000 description 1
- 101150110519 RPL25 gene Proteins 0.000 description 1
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 description 1
- 102100039790 Ran-specific GTPase-activating protein Human genes 0.000 description 1
- 101710179353 Ran-specific GTPase-activating protein Proteins 0.000 description 1
- 101710180752 Ran-specific GTPase-activating protein 1 Proteins 0.000 description 1
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 1
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 1
- 102100030542 Replication factor C subunit 4 Human genes 0.000 description 1
- 102100034373 Replication protein A 30 kDa subunit Human genes 0.000 description 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100030676 Rho GTPase-activating protein 35 Human genes 0.000 description 1
- 102100024869 Rhombotin-1 Human genes 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 108700028341 SMARCB1 Proteins 0.000 description 1
- 101150008214 SMARCB1 gene Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 description 1
- 101000770949 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) 3'-flap repair endonuclease Xpf Proteins 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 101000746496 Schizosaccharomyces pombe (strain 972 / ATCC 24843) GTP-binding protein ypt3 Proteins 0.000 description 1
- 241000252141 Semionotiformes Species 0.000 description 1
- 102100029665 Serine/arginine-rich splicing factor 3 Human genes 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100036122 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform Human genes 0.000 description 1
- 102100038901 Serine/threonine-protein phosphatase PGAM5, mitochondrial Human genes 0.000 description 1
- 102100036033 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Human genes 0.000 description 1
- 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 102000013380 Smoothened Receptor Human genes 0.000 description 1
- 101710090597 Smoothened homolog Proteins 0.000 description 1
- 101150045565 Socs1 gene Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102100022378 Sorting nexin-2 Human genes 0.000 description 1
- 102100036422 Speckle-type POZ protein Human genes 0.000 description 1
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 description 1
- 102100021916 Sperm-associated antigen 1 Human genes 0.000 description 1
- 102100028664 Sperm-associated antigen 11A Human genes 0.000 description 1
- 102100028654 Sperm-associated antigen 11B Human genes 0.000 description 1
- 102100036373 Sperm-associated antigen 16 protein Human genes 0.000 description 1
- 102100036346 Sperm-associated antigen 17 Human genes 0.000 description 1
- 102100021907 Sperm-associated antigen 4 protein Human genes 0.000 description 1
- 102100021915 Sperm-associated antigen 5 Human genes 0.000 description 1
- 102100021909 Sperm-associated antigen 6 Human genes 0.000 description 1
- 102100021912 Sperm-associated antigen 7 Human genes 0.000 description 1
- 102100021913 Sperm-associated antigen 8 Human genes 0.000 description 1
- 102100024690 Spliceosome RNA helicase DDX39B Human genes 0.000 description 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 description 1
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 description 1
- 102100024510 Src-like-adapter 2 Human genes 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 1
- 102100026939 Suppressor of fused homolog Human genes 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 102100021997 Synphilin-1 Human genes 0.000 description 1
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 101150041808 TDP1 gene Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100034939 Terminal nucleotidyltransferase 4A Human genes 0.000 description 1
- 102100034938 Terminal nucleotidyltransferase 4B Human genes 0.000 description 1
- 108700038060 Terminal nucleotidyltransferase 4B Proteins 0.000 description 1
- 102100038305 Terminal nucleotidyltransferase 5C Human genes 0.000 description 1
- 102100024872 Three prime repair exonuclease 2 Human genes 0.000 description 1
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 102100038618 Thymidylate synthase Human genes 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100026043 Transcription factor BTF3 Human genes 0.000 description 1
- 102100021783 Transcription factor E2F4 Human genes 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 description 1
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102100027065 Translation initiation factor eIF-2B subunit beta Human genes 0.000 description 1
- 102100034266 Translation initiation factor eIF-2B subunit delta Human genes 0.000 description 1
- 102100023225 Translation initiation factor eIF-2B subunit gamma Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 1
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 description 1
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 description 1
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710204576 UV excision repair protein RAD23 homolog A Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100024250 Ubiquitin carboxyl-terminal hydrolase CYLD Human genes 0.000 description 1
- 101710192923 Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 1
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000040856 WT1 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- 101150084041 WT1 gene Proteins 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- 108010007135 Werner Syndrome Helicase Proteins 0.000 description 1
- 102000007619 Werner Syndrome Helicase Human genes 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 102100039492 X antigen family member 2 Human genes 0.000 description 1
- 102100039491 X antigen family member 3 Human genes 0.000 description 1
- 102100039494 X antigen family member 5 Human genes 0.000 description 1
- 108700042462 X-linked Nuclear Proteins 0.000 description 1
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- 101100445056 Xenopus laevis elavl1-a gene Proteins 0.000 description 1
- 101100445057 Xenopus laevis elavl1-b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 102100025350 Zinc finger and BTB domain-containing protein 2 Human genes 0.000 description 1
- 102100036595 Zinc finger protein 217 Human genes 0.000 description 1
- 102100026335 Zinc finger protein 276 Human genes 0.000 description 1
- 102100028376 Zinc finger protein 703 Human genes 0.000 description 1
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000012785 antimicrobial humoral response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 102100037490 cAMP-dependent protein kinase type I-alpha regulatory subunit Human genes 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 101150095658 ilf2 gene Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010019691 inhibin beta A subunit Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 101150049514 mutL gene Proteins 0.000 description 1
- 101150029137 mutY gene Proteins 0.000 description 1
- 231100000310 mutation rate increase Toxicity 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010034343 phosphoribosylamine-glycine ligase Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000012357 postreplication repair Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000034429 protein ADP-ribosylation Effects 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
- 108050008067 rad9 Proteins 0.000 description 1
- 102000000611 rad9 Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000031267 regulation of DNA replication Effects 0.000 description 1
- 230000017641 regulation of S phase of mitotic cell cycle Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 101150027045 rplY gene Proteins 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- the field of the invention is profiling of omics data as they relate to cancer, especially as it relates to the generation of indicators for cancer prognosis, prediction of treatment outcomes, and/or effectiveness of cancer treatments.
- Cancer is a multifactorial disease where many diverse genetic and environmental factors interplay and contribute to the development and outcome of the disease.
- genetic and environmental factors often affect the patient's prognosis in various degrees such that individual patients may show different responses to the same therapeutic and/or prophylactic treatment.
- Such complexity and diversity render traditional prediction of prognosis, identification of optimal treatments, and prediction of likelihood of success of the treatments based on a single or few factors (e.g., serum level of inflammation-related proteins, etc.), often unreliable.
- many traditional methods of examining such factors are invasive as they require tumor biopsy samples for histology of tumor cells and tissues.
- the inventive subject matter is directed to methods of using various omics data of cell free nucleic acids to calculate a composite cancer score that can be used to determine the status, prognosis of a cancer as well as likelihood of treatment outcome and/or effectiveness of current treatments.
- one aspect of the subject matter includes a method of analyzing omics data.
- blood is obtained from a patient having or suspected to have a cancer.
- omics data for a plurality of cancer-related genes are obtained.
- the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data.
- a composite score is calculated which can then be associated with at least one of a health status, an omics error status, a cancer prognosis, a therapeutic recommendation, and an effectiveness of a treatment.
- the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status.
- the DNA sequence data is obtained from circulating free DNA.
- the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA.
- the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease.
- the neoepitope is tumor-specific and patient-specific.
- the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In such embodiments, it is preferred that the presence of the mutation in the cancer-specific gene weighs more than the presence of the mutation in the cancer-related genes other than the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between or among a plurality of splice variants of the cancer gene.
- the method further comprises a step of comparing the score with a threshold value to thereby determine the therapeutic recommendation.
- the therapeutic recommendation is a prophylactic treatment if the score is below the threshold value.
- the method further comprises a step of comparing the omics error status with a threshold value to thereby determine a risk score.
- the inventors contemplate a method of determining prognosis of a cancer of a patient.
- blood is obtained from a patient having or suspected to have a cancer.
- omics data for a plurality of cancer genes are obtained.
- the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data.
- a cancer prognosis score is calculated, and the prognosis of the cancer is provided based on the cancer prognosis score.
- the prognosis comprises a progress of metastasis.
- the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status.
- the DNA sequence data is obtained from circulating free DNA.
- the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA.
- the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease.
- the neoepitope is tumor-specific and patient-specific.
- the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio among or between a plurality of splice variants of the cancer gene.
- the omics data is a plurality of sets of omics data obtained at a different time points during a time period
- the prognosis is provided based on a plurality of scores from the plurality of sets of omics data.
- it is preferred that the prognosis is represented by a change of a plurality of scores during the time period, wherein the change is over a predetermined threshold value.
- Still another aspect of inventive subject matter is directed towards a method of predicting an outcome of a treatment for a cancer patient.
- blood is obtained from a patient having a cancer.
- omics data for a plurality of cancer genes are obtained.
- the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data.
- a cancer gene score is calculated, and a predicted outcome of the treatment is provided based on the cancer prognosis score.
- the predicted outcome is determined by comparing the cancer gene score with a predetermined threshold value.
- the treatment is a drug, and at least one of the plurality of cancer gene is a predicted target of the drug.
- the treatment is an immune therapy, and at least one of the plurality of cancer gene is a receptor of an immune cell or a ligand of the receptor.
- the treatment is a surgery or a radiation therapy, and at least one of the plurality of cancer gene is a neoepitope that is tumor-specific and patient-specific.
- the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status.
- the DNA sequence data is obtained from circulating free DNA.
- the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA.
- the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease.
- the neoepitope is tumor-specific and patient-specific.
- the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between a plurality of splice variants of the cancer gene.
- the inventors contemplate a method of evaluating an effectiveness of a treatment for a cancer patient.
- blood is obtained from a patient having a cancer.
- omics data for a plurality of cancer genes are obtained before and after the treatment.
- the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data.
- the effectiveness of the treatment is provided based on the comparison of the at least two cancer gene scores.
- the effectiveness of the treatment can be determined by a difference between the cancer gene score before and after the treatment. In such embodiments, it is preferred that the treatment is determined effective when the difference is higher than a predetermined threshold value.
- the treatment is a drug, and at least one of the plurality of cancer gene is a predicted target of the drug.
- the treatment is an immune therapy, and at least one of the plurality of cancer gene is a receptor of an immune cell or a ligand of the receptor.
- the treatment is a surgery or a radiation therapy, and at least one of the plurality of cancer gene is a neoepitope that is tumor-specific and patient-specific.
- the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status.
- the DNA sequence data is obtained from circulating free DNA.
- the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA.
- the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease.
- the neoepitope is tumor-specific and patient-specific.
- the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between a plurality of splice variants of the cancer gene.
- the inventors discovered that the status and/or prognosis of a cancer can be more reliably determined in a less invasive and quick manner using a compound score that is generated based on multiple factors associated with the cancer.
- the inventors also discovered that the compound score can be used to reliably predict a likelihood of outcome of a cancer treatment, and further, effectiveness of a particular cancer treatment.
- a compound score can be generated from the patient's omics data obtained from nucleic acids in the patient's blood.
- the omics data include omics data of various cancer-related genes, which can be differentially weighed based on the type and timing of the sampling.
- the compound score can be a reliable indicator to determine cancer status and/or prognosis of a cancer, a likelihood of outcome of a cancer treatment. Further, the compound scores generated based on omics data obtained before and after a cancer treatment can be compared to determine the effectiveness of a cancer treatment.
- tumor refers to, and is interchangeably used with one or more cancer cells, cancer tissues, malignant tumor cells, or malignant tumor tissue, that can be placed or found in one or more anatomical locations in a human body.
- a patient includes both individuals that are diagnosed with a condition (e.g., cancer) as well as individuals undergoing examination and/or testing for the purpose of detecting or identifying a condition.
- a patient having a tumor refers to both individuals that are diagnosed with a cancer as well as individuals that are suspected to have a cancer.
- the term “provide” or “providing” refers to and includes any acts of manufacturing, generating, placing, enabling to use, transferring, or making ready to use.
- the patient's bodily fluid includes, but is not limited to, blood, serum, plasma, mucus, cerebrospinal fluid, ascites fluid, saliva, and urine of the patient.
- various other bodily fluids are also deemed appropriate so long as cell free DNA/RNA is present in such fluids.
- the patient's bodily fluid may be fresh or preserved/frozen.
- Appropriate fluids include saliva, ascites fluid, spinal fluid, urine, etc., which may be fresh or preserved/frozen.
- the cell free RNA may include any types of DNA/RNA that are circulating in the bodily fluid of a person without being enclosed in a cell body or a nucleus.
- the source of the cell free DNA/RNA is the tumor cells.
- the source of the cell free DNA/RNA is an immune cell (e.g., NK cells, T cells, macrophages, etc.).
- the cell free DNA/RNA can be circulating tumor DNA/RNA (ctDNA/RNA) and/or circulating free DNA/RNA (cf DNA/RNA, circulating nucleic acids that do not derive from a tumor).
- the cell free DNA/RNA may be enclosed in a vesicular structure (e.g., via exosomal release of cytoplasmic substances) so that it can be protected from nuclease (e.g., RNAase) activity in some type of bodily fluid.
- nuclease e.g., RNAase
- the cell free DNA/RNA is a naked DNA/RNA without being enclosed in any membranous structure, but may be in a stable form by itself or be stabilized via interaction with one or more non-nucleotide molecules (e.g., any RNA binding proteins, etc.).
- non-nucleotide molecules e.g., any RNA binding proteins, etc.
- the cell free DNA/RNA can be any type of DNA/RNA which can be released from either cancer cells or immune cell.
- the cell free DNA may include any whole or fragmented genomic DNA, or mitochondrial DNA
- the cell free RNA may include mRNA, tRNA, microRNA, small interfering RNA, long non-coding RNA (lncRNA).
- the cell free DNA is a fragmented DNA typically with a length of at least 50 base pair (bp), 100 base pair (bp), 200 bp, 500 bp, or 1 kbp.
- the cell free RNA is a full length or a fragment of mRNA (e.g., at least 70% of full-length, at least 50% of full length, at least 30% of full length, etc.). While cell free DNA/RNA may include any type of DNA/RNA encoding any cellular, extracellular proteins or non-protein elements, it is preferred that at least some of cell free DNA/RNA encodes one or more cancer-related proteins, or inflammation-related proteins.
- the cell free DNA/mRNA may be full-length or fragments of (or derived from the) cancer related genes including, but not limited to ABL1, ABL2, ACTB, ACVR1B, AKT1, AKT2, AKT3, ALK, AMER11, APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ASXL1, ATF1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, EMSY, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDK
- genes may be wild type or mutated versions, including missense or nonsense mutations, insertions, deletions, fusions, and/or translocations, all of which may or may not cause formation of full-length mRNA when transcribed.
- some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of inflammation-related proteins, including, but not limited to, HMGB1, HMGB2, HMGB3, MUC1, VWF, MMP, CRP, PBEF1, TNF- ⁇ , TGF- ⁇ , PDGFA, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN- ⁇ , IP-10, MCP-1, PDGF, and hTERT, and in yet another example, the cell free mRNA encoded a full length or a fragment of HMGB1.
- some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of DNA repair-related proteins or RNA repair-related proteins.
- Table 1 provides an exemplary collection of predominant RNA repair genes and their associated repair pathways contemplated herein, but it should be recognized that numerous other genes associated with DNA repair and repair pathways are also expressly contemplated herein, and Tables 2 and 3 illustrate further exemplary genes for analysis and their associated function in DNA repair.
- polypeptide-like POLD2 polymerase DNA replication///DNA replication DNA directed
- RPA1 replication DNA-dependent DNA replication///DNA protein A1, repair///DNA recombination///DNA 70 kDa replication
- pombe cell cycle checkpoint///DNA damage checkpoint///DNA repair///response to DNA damage stimulus///meiotic prophase I BRCA1 breast cancer 1, regulation of transcription from RNA early onset polymerase II promoter///regulation of transcription from RNA polymerase III promoter///DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator///cell cycle///protein ubiquitination///androgen receptor signaling pathway////regulation of cell proliferation////regulation of apoptosis//// positive regulation of DNA repair/// negative regulation of progression through cell cycle///positive regulation of transcription, DNA-dependent/// negative regulation of centriole replication////DNA damage response, signal transduction resulting in induction of apoptosis///DNA repair///response to DNA damage stimulus///protein ubiquitination//DNA repair///regulation of DNA repair///apoptosis
- DNA damage stimulus POLE2 polymerase DNA DNA replication///DNA repair///DNA directed
- epsilon replication 2 p59 subunit
- RAD51C RAD51 homolog DNA repair///DNA recombination///DNA C
- DNA metabolism///DNA repair///mismatch repair///response to DNA damage stimulus///DNA repair RPA3 replication DNA replication///DNA repair///DNA protein A3, 14 kDa MBD4 methyl- replication base-excision repair///DNA CpG binding repair///response to DNA damage domain stimulus///DNA repair protein 4 MBD4 methyl-CpG base-excision repair///DNA repair/// binding domain response to DNA damage stimulus/// protein 4 DNA repair NTHL1 nth endonuclease carbohydrate metabolism///base-excision III-like 1 repair///nucleotide-excision repair, DNA ( E.
- pombe cell cycle checkpoint///DNA damage checkpoint///DNA repair///response to DNA damage stimulus/// meiotic prophase I RECQL5 RecQ protein- DNA repair///DNA metabolism//DNA like 5 metabolism MSH5 mutS homolog 5 DNA metabolism///mismatch repair/// ( E. coli ) mismatch repair///meiosis///meiotic recombination///meiotic prophase II/// meiosis RECQL RecQ protein- DNA repair///DNA metabolism like (DNA helicase Q1-like) RAD52 RAD52 homolog double-strand break repair///mitotic (S.
- telomerase-dependent telomere maintenance///meiosis///meiotic recombination///DNA metabolism/// DNA repair////double-strand break repair///response to DNA damage stimulus///DNA repair///double-strand break repair///DNA recombination MSH6 mutS homolog 6 mismatch repair///DNA metabolism/// ( E. coli ) DNA repair///mismatch repair///response to DNA damage stimulus MSH6 mutS homolog 6 mismatch repair///DNA metabolism/// ( E.
- DNA repair///mismatch repair/// response to DNA damage stimulus RECQL5 RecQ protein- DNA repair///DNA metabolism///DNA like 5 metabolism BRCA1 breast cancer 1, regulation of transcription from RNA early onset polymerase II promoter///regulation of transcription from RNA polymerase III promoter///DNA damage response, signal transduction by p53 class mediator resultingi n transcription of p21 class mediator///cell cycle///protein ubiquitination///androgen receptor signaling pathway////regulation of cell proliferation////regulation of apoptosis///positive regulation of DNA repair///negative regulation of progression through cell cycle/// positive regulation of transcription, DNA-dependent///negative regulation of centriole replication////DNA damage response, signal transduction resulting in induction of apoptosis///DNA repair/// response to DNA damage stimulus/// protein ubiquitination///DNA repair/// regulation of DNA repair///apoptosis//
- DNA repair///mismatch repair/// response to DNA damage stimulus/// mismatch repair FANCA Fanconi anemia, DNA repair///protein complex assembly/// complementation DNA repair///response to DNA damage group
- DNA repair///mismatch repair/// response to DNA damage stimulus/// mismatch repair NBN nibrin DNA damage checkpoint///cell cycle checkpoint////double-strand break repair SMUG1 single-strand carbohydrate metabolism///DNA repair/// selective response to DNA damage stimulus monofunctional uracil DNA glycosylase
- FANCF Fanconi anemia DNA repair///response to DNA damage complementation stimulus group
- F NEIL1 nei endonuclease carbohydrate metabolism///DNA repair/// VIII-like 1 response to DNA damage stimulus E.
- some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of a gene not associated with a disease (e.g., housekeeping genes), including, but not limited to, those related to transcription factors (e.g., ATF1, ATF2, ATF4, ATF6, ATF7, ATFIP, BTF3, E2F4, ERH, HMGB1, ILF2, IER2, JUND, TCEB2, etc.), repressors (e.g., PUF60), RNA splicing (e.g., BAT1, HNRPD, HNRPK, PABPN1, SRSF3, etc.), translation factors (EIF1, EIF1AD, EIF1B, EIF2A, EIF2AK1, EIF2AK3, EIF2AK4, EIF2B2, EIF2B3, EIF2B4, EIF2S2, EIF3A, etc.), tRNA synthetases (e.g., AARS, CARS, DARS
- transcription factors
- ATP2C1, ATP5F1, etc. lysosome
- proteasome e.g., PSMA1, UBA1, etc.
- cytoskeletal proteins e.g., ANXA6, ARPC2, etc.
- organelle synthesis e.g., BLOC1S1, AP2A1, etc.
- some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of a neoepitope specific to the tumor.
- neoepitope it should be appreciated that neoepitopes can be characterized as random mutations in tumor cells that create unique and tumor specific antigens. Therefore, high-throughput genome sequencing should allow for rapid and specific identification of patient specific neoepitopes where the analysis also considers matched normal tissue of the same patient.
- neoepitopes may be identified from a patient tumor in a first step by whole genome analysis of a tumor biopsy (or lymph biopsy or biopsy of a metastatic site) and matched normal tissue (i.e., non-diseased tissue from the same patient) via synchronous comparison of the so obtained omics information.
- the data are patient matched tumor data (e.g., tumor versus same patient normal), and that the data format is in SAM, BAM, GAR, or VCF format.
- non-matched or matched versus other reference e.g., prior same patient normal or prior same patient tumor, or homo statisticus
- the omics data may be ‘fresh’ omics data or omics data that were obtained from a prior procedure (or even different patient). However, and especially where genomics ctDNA is analyzed, the neoepitope-coding sequence need not necessarily be expressed.
- the nucleic acid encoding a neoepitope may encode a neoepitope that is also a suitable target for immune therapy. Therefore, neoepitopes can then be further filtered for a match to the patient's HLA type to thereby increase likelihood of antigen presentation of the neoepitope. Most preferably, and as further discussed below, such matching can be done in silico.
- the patient-specific epitopes are unique to the patient, but may also in at least some cases include tumor type-specific neoepitopes (e.g., Her-2, PSA, brachyury) or cancer-associated neoepitopes (e.g., CEA, MUC-1, CYPB1).
- tumor type-specific neoepitopes e.g., Her-2, PSA, brachyury
- cancer-associated neoepitopes e.g., CEA, MUC-1, CYPB1
- cell free DNA/mRNA may present in modified forms or different isoforms.
- the cell free DNA may be present in methylated or hydroxyl methylated, and the methylation level of some genes (e.g., GSTP1, p16, APC, etc.) may be a hallmark of specific types of cancer (e.g., colorectal cancer, etc.).
- the cell free mRNA may be present in a plurality of isoforms (e.g., splicing variants, etc.) that may be associated with different cell types and/or location.
- different isoforms of mRNA may be a hallmark of specific tissues (e.g., brain, intestine, adipose tissue, muscle, etc.), or may be a hallmark of cancer (e.g., different isoform is present in the cancer cell compared to corresponding normal cell, or the ratio of different isoforms is different in the cancer cell compared to corresponding normal cell, etc.).
- tissue e.g., brain, intestine, adipose tissue, muscle, etc.
- cancer e.g., different isoform is present in the cancer cell compared to corresponding normal cell, or the ratio of different isoforms is different in the cancer cell compared to corresponding normal cell, etc.
- mRNA encoding HMGB1 are present in 18 different alternative splicing variants and 2 unspliced forms.
- isoforms are expected to express in different tissues/locations of the patient's body (e.g., isoform A is specific to prostate, isoform B is specific to brain, isoform C is specific to spleen, etc.).
- identifying the isoforms of cell free mRNA in the patient's bodily fluid can provide information on the origin (e.g., cell type, tissue type, etc.) of the cell free mRNA.
- regulatory noncoding RNA e.g., microRNA, small interfering RNA, long non-coding RNA (lncRNA)
- lncRNA long non-coding RNA
- varied expression of regulatory noncoding RNA in a cancer patient's bodily fluid may due to genetic modification of the cancer cell (e.g., deletion, translocation of parts of a chromosome, etc.), and/or inflammations at the cancer tissue by immune system (e.g., regulation of miR-29 family by activation of interferon signaling and/or virus infection, etc.).
- the cell free RNA can be a regulatory noncoding RNA that modulates expression (e.g., downregulates, silences, etc.) of mRNA encoding a cancer-related protein or an inflammation-related protein (e.g., HMGB1, HMGB2, HMGB3, MUC1, VWF, MMP, CRP, PBEF1, TNF- ⁇ , TGF- ⁇ , PDGFA, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN- ⁇ , IP-10, MCP-1, PDGF, hTERT, etc.).
- a regulatory noncoding RNA that modulates expression (e.g., downregulates, silences, etc.) of mRNA encoding a cancer-related protein or an inflammation-related protein (e.g
- some cell free regulatory noncoding RNA may be present in a plurality of isoforms or members (e.g., members of miR-29 family, etc.) that may be associated with different cell types and/or location.
- different isoforms or members of regulatory noncoding RNA may be a hallmark of specific tissues (e.g., brain, intestine, adipose tissue, muscle, etc.), or may be a hallmark of cancer (e.g., different isoform is present in the cancer cell compared to corresponding normal cell, or the ratio of different isoforms is different in the cancer cell compared to corresponding normal cell, etc.).
- identifying the isoforms of cell free regulatory noncoding RNA in the patient's bodily fluid can provide information on the origin (e.g., cell type, tissue type, etc.) of the cell free regulatory noncoding RNA.
- cell free DNA/RNA is isolated from a bodily fluid (e.g., whole blood) that is processed under a suitable conditions, including a condition that stabilizes cell free RNA.
- a bodily fluid e.g., whole blood
- both cell free DNA and RNA are isolated simultaneously from the same badge of the patient's bodily fluid.
- the bodily fluid sample can be divided into two or more smaller samples from which DNA or RNA can be isolated separately.
- the bodily fluid of the patient can be obtained at any desired time point(s) depending on the purpose of the omics analysis.
- the bodily fluid of the patient can be obtained before and/or after the patient is confirmed to have a tumor and/or periodically thereafter (e.g., every week, every month, etc.) in order to associate the cell free DNA/RNA data with the prognosis of the cancer.
- the bodily fluid of the patient can be obtained from a patient before and after the cancer treatment (e.g., chemotherapy, radiotherapy, drug treatment, cancer immunotherapy, etc.). While it may vary depending on the type of treatments and/or the type of cancer, the bodily fluid of the patient can be obtained at least 24 hours, at least 3 days, at least 7 days after the cancer treatment.
- the bodily fluid from the patient before the cancer treatment can be obtained less than 1 hour, less than 6 hours before, less than 24 hours before, less than a week before the beginning of the cancer treatment.
- a plurality of samples of the bodily fluid of the patient can be obtained during a period before and/or after the cancer treatment (e.g., once a day after 24 hours for 7 days, etc.).
- the bodily fluid of a healthy individual can be obtained to compare the sequence/modification of cell free DNA, and/or quantity/subtype expression of cell free RNA.
- a healthy individual refers an individual without a tumor.
- the healthy individual can be chosen among group of people shares characteristics with the patient (e.g., age, gender, ethnicity, diet, living environment, family history, etc.).
- any suitable methods for isolating cell free DNA/RNA are contemplated.
- specimens were accepted as 10 ml of whole blood drawn into a test tube.
- Cell free DNA can be isolated from other from mono-nucleosomal and di-nucleosomal complexes using magnetic beads that can separate out cell free DNA at a size between 100-300 bps.
- specimens were accepted as 10 ml of whole blood drawn into cell-free RNA BCT® tubes or cell-free DNA BCT® tubes containing RNA stabilizers, respectively.
- cell free RNA is stable in whole blood in the cell-free RNA BCT tubes for seven days while cell free RNA is stable in whole blood in the cell-free DNA BCT Tubes for fourteen days, allowing time for shipping of patient samples from world-wide locations without the degradation of cell free RNA.
- the cell free RNA is isolated using RNA stabilization agents that will not or substantially not (e.g., equal or less than 1%, or equal or less than 0.1%, or equal or less than 0.01%, or equal or less than 0.001%) lyse blood cells.
- the RNA stabilization reagents will not lead to a substantial increase (e.g., increase in total RNA no more than 10%, or no more than 5%, or no more than 2%, or no more than 1%) in RNA quantities in serum or plasma after the reagents are combined with blood.
- these reagents will also preserve physical integrity of the cells in the blood to reduce or even eliminate release of cellular RNA found in blood cell. Such preservation may be in form of collected blood that may or may not have been separated.
- contemplated reagents will stabilize cell free RNA in a collected tissue other than blood for at 2 days, more preferably at least 5 days, and most preferably at least 7 days.
- numerous other collection modalities are also deemed appropriate, and that the cell free RNA can be at least partially purified or adsorbed to a solid phase to so increase stability prior to further processing.
- fractionation of plasma and extraction of cell free DNA/RNA can be done in numerous manners.
- whole blood in 10 mL tubes is centrifuged to fractionate plasma at 1600 rcf for 20 minutes.
- the so obtained plasma is then separated and centrifuged at 16,000 rcf for 10 minutes to remove cell debris.
- various alternative centrifugal protocols are also deemed suitable so long as the centrifugation will not lead to substantial cell lysis (e.g., lysis of no more than 1%, or no more than 0.1%, or no more than 0.01%, or no more than 0.001% of all cells).
- Cell free RNA is extracted from 2 mL of plasma using Qiagen reagents.
- the extraction protocol was designed to remove potential contaminating blood cells, other impurities, and maintain stability of the nucleic acids during the extraction. All nucleic acids were kept in bar-coded matrix storage tubes, with DNA stored at ⁇ 4° C. and RNA stored at ⁇ 80° C. or reverse-transcribed to cDNA that is then stored at ⁇ 4° C. Notably, so isolated cell free RNA can be frozen prior to further processing.
- DNA sequence data will not only include the presence or absence of a gene that is associated with cancer or inflammation, but also take into account mutation data where the gene is mutated, the copy number (e.g., to identify duplication, loss of allele or heterozygosity), and epigenetic status (e.g., methylation, histone phosphorylation, nucleosome positioning, etc.).
- mutation data e.g., to identify duplication, loss of allele or heterozygosity
- epigenetic status e.g., methylation, histone phosphorylation, nucleosome positioning, etc.
- contemplated RNA sequence data include mRNA sequence data, splice variant data, polyadenylation information, etc.
- the RNA sequence data also include a metric for the transcription strength (e.g., number of transcripts of a damage repair gene per million total transcripts, number of transcripts of a damage repair gene per total number of transcripts for all damage repair genes, number of transcripts of a damage repair gene per number of transcripts for actin or other household gene RNA, etc.), and for the transcript stability (e.g., a length of poly A tail, etc.).
- a metric for the transcription strength e.g., number of transcripts of a damage repair gene per million total transcripts, number of transcripts of a damage repair gene per total number of transcripts for all damage repair genes, number of transcripts of a damage repair gene per number of transcripts for actin or other household gene RNA, etc.
- transcript stability e.g., a length of poly A tail, etc.
- transcription strength of the cell free RNA can be examined by quantifying the cell free RNA.
- Quantification of cell free RNA can be performed in numerous manners, however, expression of analytes is preferably measured by quantitative real-time RT-PCR of cell free RNA using primers specific for each gene. For example, amplification can be performed using an assay in a 10 ⁇ L reaction mix containing 2 ⁇ L cell free RNA, primers, and probe. mRNA of ⁇ -actin can be used as an internal control for the input level of cell free RNA. A standard curve of samples with known concentrations of each analyte was included in each PCR plate as well as positive and negative controls for each gene.
- Test samples were identified by scanning the 2D barcode on the matrix tubes containing the nucleic acids.
- Delta Ct was calculated from the Ct value derived from quantitative PCR (qPCR) amplification for each analyte subtracted by the Ct value of actin for each individual patient's blood sample.
- Relative expression of patient specimens is calculated using a standard curve of delta Cts of serial dilutions of Universal Human Reference RNA set at a gene expression value of 10 (when the delta CTs were plotted against the log concentration of each analyte).
- real time quantitative PCR may be replaced by RNAseq to so cover at least part of a patient transcriptome.
- analysis can be performed static or over a time course with repeated sampling to obtain a dynamic picture without the need for biopsy of the tumor or a metastasis.
- genomic data of cell free DNA/RNA preferably comprise a genomic data set that includes genomic sequence information.
- the genomic sequence information comprises DNA sequence information of cell free DNA of the patient and optionally cell free DNA of a healthy individual.
- the sequence data sets may include unprocessed or processed data sets, and exemplary data sets include those having BAM format, SAM format, FASTQ format, or FASTA format.
- BAM format or as BAMBAM diff objects (see e.g., US2012/0059670A1 and US2012/0066001A1).
- the data sets are reflective of the cell free DNA/RNA of the patient and of the healthy individual to so obtain patient and tumor specific information.
- omics information can then be processed using pathway analysis (especially using PARADIGM) to identify any impact of any mutations on DNA repair pathways.
- sequence data may be performed in numerous manners. In most preferred methods, however, analysis is performed in silico by location-guided synchronous alignment of cell free DNA/RNA of the patient and a healthy individual as, for example, disclosed in US 2012/0059670A1 and US 2012/0066001A1 using BAM files and BAM servers. Such analysis advantageously reduces false positive data and significantly reduces demands on memory and computational resources.
- differential sequence object is generated by incremental synchronous alignment of BAM files representing genomic sequence information of the cell free DNA/RNA of the patient and a healthy individual.
- particularly preferred methods include BAMBAM-based methods as described in US 2012/0059670 and US 2012/0066001.
- a library or reference base for all cancer-related genes, inflammation-related genes, DNA repair-related genes, and/or other non-disease related housekeeping genes can be created using one or more omics data for each of those genes, and such library is particularly useful where the omics data are associated with one or more health parameter.
- such library can provide a tool to generate a large cross-sectional database for all cancer-related gene activity, inflammation-related gene activity, DNA repair gene activity and housekeeping gene activity (as a control).
- the large cross-sectional database can be a basis for generating a cancer matrix, based on which a prognosis of a cancer, a health status of the patient, a likelihood of outcome of treatment, an effectiveness of the treatment can be more reliably calculated.
- analyses presented herein may be performed over specific and diverse populations to so obtain reference values for the specific populations, such as across various health associated states (e.g., healthy, diagnosed with a specific disease and/or disease state, which may or may not be inherited, or which may or may not be associated with impaired DNA repair, inflammation-related autoimmunity, etc.), a specific age or age bracket, a specific ethnic group that may or may not be associated with frequent occurrence of specific type of cancer.
- populations may also be enlisted from databases with known omics information, and especially publically available omics information from cancer patients (e.g., TCGA, COSMIC, etc.) and proprietary databases from a large variety of individuals that may be healthy or diagnosed with a disease.
- the population records may also be indexed over time for the same individual or group of individuals, which advantageously allows detection of shifts or changes in the genes and pathways associated with different types of cancers.
- a cancer score can be established for one or more cancer-related genes, inflammation-related genes, a DNA-repair gene, a neoepitope, and a gene not associated with a disease and that the score may be reflective of or even prognostic for various types of cancer that are at least in part due to mutations in cancer-related genes and/or pathways.
- suitable cancer scores may involve scores for one or more genes associated with one or more types of cancer (e.g., BRCA1, BRCA2, P53, etc.) relative to another gene that may or may not be associated with one type of cancer (e.g., housekeeping genes, etc.).
- contemplated cancer scores may involve scores for one or more genes associated with one or more types of one or more types of cancer (e.g., BRCA1, BRCA2, P53, etc.) relative to an overall mutation rate (e.g., mutation rate of the genes not associated with a disease, etc.) to so better identify cancer relevant mutations over ‘background’ mutations.
- an overall mutation rate e.g., mutation rate of the genes not associated with a disease, etc.
- the omics data may be used to generate a general error status for an individual (or tumor within an individual), or to associate the number and/or type of alterations in cancer-related genes, inflammation-related genes, or a DNA-repair gene to identify a ‘tipping point’ for one or more gene mutations after which a general mutation rate skyrockets.
- a rate or number of mutations in ERCC1 and other DNA repair genes could have only minor systemic consequence, addition of further mutations to TP53 may result in a catastrophic increase in mutation rates.
- mutations in the genes associated with DNA may be used to estimate the risk of occurrence for a DNA damage-based disease, and especially cancer and age-related diseases.
- omics information may be analyzed in one or more pathway analysis algorithms (e.g., PARADIGM) to so identify affected pathways and to so possibly adjust treatment where treatment employs DNA damaging agents.
- Pathway analysis algorithms may also be used to in silico modulate expression of one or more DNA repair genes, which may results in desirable or even unexpected in silico treatment outcomes, which may be translated into the clinic.
- the cancer score is typically a compound score reflecting status of a plurality of genes.
- the cancer score can be calculated by counting any mutations (e.g., deletion, missense, nonsense, etc.) of any cancer-related genes, inflammation-related genes, and DNA-repair genes with one or more mutations as having a positive value, counting any changes in methylation or other modifications in DNA of counting any cancer-related genes, DNA-repair genes, counting any upregulation or downregulation in expression levels of RNA of any cancer-related genes, inflammation-related genes, and DNA-repair genes, counting any presence of tumor-specific, patient specific neoepitopes, counting any changes or ratios in RNA isotypes (splice variants) of counting any cancer-related genes and DNA-repair genes, and counting any changes in length of poly A tail of any cancer-related genes, inflammation-related genes, and DNA-repair genes.
- any mutations e.g., deletion, missense, nonsense, etc.
- each count may be weighed uniformly or biased, based on the significance of each count and then be assigned a value according to the weight of each count (e.g., each count corresponds to 1 point, some counts correspond to different scores such as 1 point, 3 points, 10 points, 100 points, etc.).
- Some mutations in some cancer related genes may be ‘leading indicators’ or triggers to activate other tumorigenesis mechanism or metastasis. Identification of such triggers may advantageously allow for early diagnosis or intervention of the cancer.
- a mutation in a cancer-specific gene among cancer-related genes, inflammation-related genes, or DNA-repair genes may be weighed higher than other cancer-related genes or DNA-repair genes (e.g., at least 3 times, at least 5 times, at least 10 times, at least 100 times, etc.) and can be assigned to higher values accordingly.
- the cancer-specific gene refers any gene or mutation of the gene that is a known genetic disposition (e.g., significantly increase a susceptibility to the disease) of specific types of cancer (e.g., BRCA1 and BRCA2 for breast cancer and ovarian cancer, etc.).
- each gene in any cancer-related pathway or DNA-repair pathway may be differently weighed (e.g., most significant, significant, moderate, less significant, insignificant, etc.) and any mutation of a such gene that has any or no impact (e.g., adversely affect the pathway stream, etc.) on any cancer-related pathway or DNA-repair pathway may be weighed differently based on the significance of the impact.
- gene A encoding a significant, unreplaceable protein A in a cancer pathway may be weighed heavier than another gene B encoding a redundant protein (replaceable with other proteins).
- a nonsense mutation in gene A that results in nonfunctional protein may be weighed at least 3 times, at least 5 times, at least 10 times, at least 100 times than a silent mutation in gene A or a missense mutation which does not affect the function of protein A and can be assigned to higher values accordingly.
- some countings may weigh equally or differently based on the significance of each counting and then be assigned to a negative value according to the weight of each counting (e.g., each counting corresponds to ⁇ 1 point, some countings correspond to different scores such as ⁇ 1 point, ⁇ 3 points, ⁇ 10 points, ⁇ 100 points, etc.).
- upregulation of mRNA of gene C which can compensate the loss of function of gene A, can be assigned to a negative value (e.g., ⁇ 10 points) such that it can compensate the positive value of mutation of gene A (e.g., +10 points).
- some countings may be differently weighed based on the degree of changes in expression level of some RNAs. For example, when the expression level of RNA “X” increases at least twice, at least 5 times, at least 10 times, at least 20 times, while other RNA expression level change is below 50% at best, then the increase of expression level of RNA “X” may be weighed at least 3 times, at least 5 times, at least 10 times, at least 100 times than other genes.
- the cancer score is compound score that is a total sum of all values assigned to all counts.
- the cancer score can be a total sum of all values assigned to all counts (all omics data).
- the cancer score can be a total sum of a selected number of values assigned to some counts (e.g., corresponding to specific pathways, specific types of genes, specific groups of mechanisms, etc.).
- the cancer score increases as more cancer-related genes or DNA-repair genes possess one or more mutations.
- each mutation and/or change may be counted separately such that cancer scores may further increase where one or more cancer-related genes or DNA-repair genes show multiple mutations in a single gene.
- cancer score may further increase when such multiple mutations in a single gene may further affect the function of the cancer-related genes or DNA-repair genes such that the multiple mutations drive the cells more cancer-prone, or more cancerous, or drive the cancer microenvironment more immune-resistant, and so on.
- the cancer score can be presented as a trajectory with one or more counts as its vectors, where a few numbers of variables and/or factors dominantly govern in determination of cancer prognosis.
- Each of variables and/or factors can be presented as a vector, whose amplitude is corresponding to the point of each weighted counting, and the addition of those vectors provides a trajectory indicating the prognosis of the disease.
- multiple analyses over time can be prepared for the same patient, and that changes over time (e.g., with or without treatment) may be assigned specific values that will yet again generate a time-dependent score. Such scores or changes over time may be classified and serve as leading indicator for treatment outcome, drug response, etc.
- the cancer score can be calculated with health information other than cf/ct nucleic acid data obtained from the patient's blood.
- the health information may include expression levels/concentrations of several types of cytokines (e.g., IL-2, TNF- ⁇ , etc.) related to tumorigenesis/inflammation/immune response against the tumor, hormone levels (e.g., estrogen, progesterone, growth hormone, etc.), blood sugar level, alanine transaminase level (for liver function), creatine level (for kidney function), blood pressure, types and quantity of tumor cell-secreted proteins (e.g., soluble ligands of immune cell receptor, etc.) or foreign antigenic proteins (e.g., for virus or bacterial infection, etc.).
- cytokines e.g., IL-2, TNF- ⁇ , etc.
- hormone levels e.g., estrogen, progesterone, growth hormone, etc.
- blood sugar level e.g., alanine transamina
- the so obtained cancer score can be used to provide a diagnosis of cancer or risk of having or developing a cancer.
- the calculated cancer score of a patient can be compared with an average cancer score of healthy individuals to determine the difference between two scores.
- the patient may be diagnosed to have a tumor, or has a high risk to have a tumor.
- the calculated cancer score of a patient can be compared with a predetermined threshold score.
- the predetermined threshold score can be a predetermined score, which may vary depending on patient's ethnicity, age, gender, or other health status.
- the predetermined threshold score can a dynamic score that can be changed based on a previous cancer score and a diagnosis or treatment performed to the patient.
- the so obtained cancer score can be used to provide a prognosis of the cancer.
- the cancer scores can be calculated based on omics data obtained in month 1, month 3, month 6, and month 12 after the patient got diagnosed with a first stage of lung cancer, and each cancer score can be compared with a predetermined threshold score corresponding to the month 1, 3, 6, and 12.
- the cancer scores are about 120% of the threshold score in month 1 and 3, and the cancer score is about 180% in month 6, and 230% of the threshold score month 12.
- the cancer score can be calculated by highly weighing the presence of neoepitopes that are tumor-specific and patient-specific.
- the cancer scores can be calculated based on omics data obtained in month 1, month 3, month 6, and month 12 after the patient got diagnosed with a first stage of lung cancer, and each cancer score is calculated by highly weighing the presence/appearance of new epitope that is tumor/tissue specific.
- the cancer scores are about 120% of the threshold score in month 1 and 3, and the cancer score is about 140% in month 6, and 230% of the threshold score month 12.
- the cancer scores can provide an indicator for treatment options.
- the treatment option may be a prophylactic treatment where the compound score is below the threshold value, indicating that the patient is unlikely to have a tumor for now or at least has low risk of developing a tumor.
- a cancer-related gene A e.g., over a threshold such as at least 10%, at least 20%, at least 30%, at least 50%, etc.
- the cancer score can be used to provide the treatment option that may use a drug inhibiting the activity of cancer-related gene A (e.g., a blocker of protein A, etc.).
- cancer score when the cancer score is above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a gene encoding a receptor of an immune cell or a ligand of the receptor, then the cancer score can be used to provide the immunotherapy using the receptor or ligand of the immune cells. Also, when the cancer score is above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a specific neoepitope, then the cancer score can be used to provide the immunotherapy using the neoepitope as a bait or a surgery/a radiation therapy to physically remove local tumors. Also such cancer scores may be an indicative of likelihood of success for the treatment option. However, if the portion of the cancer score highly weighted was overexpression of a cancer-related gene A is below the threshold, then the treatment option using a drug inhibiting the activity of cancer-related gene A may be predicted less effective.
- the patient can be treated with at least one of the treatment options based on the patient's cancer (compound) score.
- the treatment option can be selected to include a recombinant virus (or yeast or bacteria) comprising a nucleic acid encoding the specific neoepitope.
- the recombinant virus can be administered to the patient in a dose and schedule effective to treat the tumor and/or effective to reduce the cancer score of the patient for at least 10%, at least 20%, at least 30%, at least in 2 weeks, at least in 4 weeks, at least in 8 weeks, at least in 12 weeks after the administration or a series of administrations.
- the patient's cancer score can be compared with one or more other patients having same type of cancer and having a treatment history to provide a treatment option and predicted outcome. For example, where other patients' history indicates that the drug treatment is effective only when the cancer score is below 200 (as absolute score), or less than 180% of the healthy individual's score, and the patient's cancer score has been increasing from 140 to 160 for the last 2 weeks, a recommendation to proceed with drug treatment no later than 2 weeks can be provided based on the other patients' history and cancer scores.
- the calculated cancer score can also be an indicator of an effectiveness of a cancer treatment, especially when the omics data includes information of at least one or more genes encoding a target/indicator of the cancer treatment.
- cancer scores can be calculated based on omics data obtained before the cancer treatment, 7 days after, 2 weeks, 1 month, and 6 months of the cancer treatment.
- the cancer score of 7 days after the treatment is 80% of the cancer score before the treatment, and the cancer score of 2 weeks and 1 month after the treatment is 50% of the cancer score before the treatment, and the cancer score of 6 months after the treatment is 150% of the cancer score before the treatment.
- the cancer scores before and after treatment can be compared with a predetermined threshold value to determine the effectiveness of the treatment. For example, if the cancer score is 200 before the treatment and 130 after the treatment where the threshold cancer score is 100, then the treatment can be determined “effective” as the cancer score drops below the threshold after the treatment. However, if the cancer score is 200 before the treatment and 160 after the treatment where the threshold cancer score is 150, then the treatment can be determined “not effective” as the cancer score stays above the threshold after the treatment even though the absolute value of the cancer score is decreased.
- the inventors further contemplate that the patient continues with administering the treatment option (e.g., immune therapy, etc.) when the treatment can be determined “effective”, when the cancer score after the treatment is lower than the predetermined threshold, when the cancer score after the treatment is at most 5%, at most 10% higher than the predetermined threshold, or when the cancer score after the treatment is at least 5%, at least 10%, at least 15% lower than the predetermined threshold.
- the treatment option e.g., immune therapy, etc.
- the effectives of some cancer treatments can be determined by analyzing omics data including foreign DNA/RNA originated from a carrier of the immune therapy (e.g., virus, bacteria, yeast, etc.).
- a carrier of the immune therapy e.g., virus, bacteria, yeast, etc.
- the virus is a carrier to deliver a recombinant nucleic acid encoding recombinant killer activation receptor (KAR)
- KAR recombinant killer activation receptor
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Methods for analyzing omics data and using the omics data to determine prognosis of a cancer, to predict an outcome of a treatment, and/or to determine an effectiveness of a treatment are presented. In preferred methods, blood from a patient having a cancer or suspected to have a cancer is obtained and blood omics data for a plurality of cancer-related, inflammation-related, or DNA repair-related genes are obtained. A cancer score can be calculated based on the omics data, which then can be used to provide a cancer prognosis, a therapeutic recommendation, an effectiveness of a treatment.
Description
- This application is a divisional application of allowed US application having Ser. No. 16/754,088, which was filed Apr. 6, 2020, and which is a 371 application of PCT/US2018/055481, which was filed Oct. 11, 2018, and which claims priority to US provisional application having the Ser. No. 62/571,414, filed Oct. 12, 2017, all of which are incorporated by reference in their entirety herein.
- The field of the invention is profiling of omics data as they relate to cancer, especially as it relates to the generation of indicators for cancer prognosis, prediction of treatment outcomes, and/or effectiveness of cancer treatments.
- The background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
- All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
- Cancer is a multifactorial disease where many diverse genetic and environmental factors interplay and contribute to the development and outcome of the disease. In addition, genetic and environmental factors often affect the patient's prognosis in various degrees such that individual patients may show different responses to the same therapeutic and/or prophylactic treatment. Such complexity and diversity render traditional prediction of prognosis, identification of optimal treatments, and prediction of likelihood of success of the treatments based on a single or few factors (e.g., serum level of inflammation-related proteins, etc.), often unreliable. Further, many traditional methods of examining such factors are invasive as they require tumor biopsy samples for histology of tumor cells and tissues.
- More recently, DNA or RNA populations present in the peripheral blood have drawn attention for analyzing genetic abnormalities associated with the cancer status. For example, U.S. Pat. No. 9,422,592 discloses the measurement of cell free RNA (cfRNA) of formulpeptide receptor gene (FPR1) and its association with the patient's risk for having lung cancer or non-small cell lung cancer (NSCLC). Yet, such studies are limited to a few numbers of genes, which are typically weighed equally in determining the cancer status. As multiple factors affect to various degrees prognosis of most cancers, oversimplification may cause inaccurate prognosis and/or prediction of treatment outcome.
- Thus, even though some examples of using cell free nucleic acid in determining cancer status are known, differentially weighed, multi-factor approaches in determining cancer status using cell free nucleic acid are largely unexplored. Thus, there remains a need for improved methods of analyzing omics data of cell free nucleic acids in determining status, prognosis of a cancer as well as likelihood of treatment outcome or effectiveness of the treatment.
- The inventive subject matter is directed to methods of using various omics data of cell free nucleic acids to calculate a composite cancer score that can be used to determine the status, prognosis of a cancer as well as likelihood of treatment outcome and/or effectiveness of current treatments. Thus, one aspect of the subject matter includes a method of analyzing omics data. In this method, blood is obtained from a patient having or suspected to have a cancer. From the blood, omics data for a plurality of cancer-related genes are obtained. Most preferably, the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data. From the omics data, a composite score is calculated which can then be associated with at least one of a health status, an omics error status, a cancer prognosis, a therapeutic recommendation, and an effectiveness of a treatment.
- In some embodiments, the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status. Optionally, the DNA sequence data is obtained from circulating free DNA. In other embodiments, the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA. Optionally, the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- Typically, the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease. Preferably, the neoepitope is tumor-specific and patient-specific. In some embodiments, the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In such embodiments, it is preferred that the presence of the mutation in the cancer-specific gene weighs more than the presence of the mutation in the cancer-related genes other than the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between or among a plurality of splice variants of the cancer gene.
- In some embodiments, the method further comprises a step of comparing the score with a threshold value to thereby determine the therapeutic recommendation. In such embodiments, it is preferred that the therapeutic recommendation is a prophylactic treatment if the score is below the threshold value. Alternatively and/or additionally, the method further comprises a step of comparing the omics error status with a threshold value to thereby determine a risk score.
- In another aspect of the inventive subject matter, the inventors contemplate a method of determining prognosis of a cancer of a patient. In this method, blood is obtained from a patient having or suspected to have a cancer. From the blood, omics data for a plurality of cancer genes are obtained. Preferably, the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data. From the omics data, a cancer prognosis score is calculated, and the prognosis of the cancer is provided based on the cancer prognosis score. IN some embodiments, the prognosis comprises a progress of metastasis.
- In some embodiments, the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status. Optionally, the DNA sequence data is obtained from circulating free DNA. In other embodiments, the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA. Optionally, the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- Typically, the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease. Preferably, the neoepitope is tumor-specific and patient-specific. In some embodiments, the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio among or between a plurality of splice variants of the cancer gene.
- In some embodiments, the omics data is a plurality of sets of omics data obtained at a different time points during a time period, and the prognosis is provided based on a plurality of scores from the plurality of sets of omics data. In such embodiments, it is preferred that the prognosis is represented by a change of a plurality of scores during the time period, wherein the change is over a predetermined threshold value.
- Still another aspect of inventive subject matter is directed towards a method of predicting an outcome of a treatment for a cancer patient. In this method, blood is obtained from a patient having a cancer. From the blood, omics data for a plurality of cancer genes are obtained. Preferably, the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data. From the omics data, a cancer gene score is calculated, and a predicted outcome of the treatment is provided based on the cancer prognosis score. Preferably, the predicted outcome is determined by comparing the cancer gene score with a predetermined threshold value.
- In some embodiments, the treatment is a drug, and at least one of the plurality of cancer gene is a predicted target of the drug. In other embodiments, the treatment is an immune therapy, and at least one of the plurality of cancer gene is a receptor of an immune cell or a ligand of the receptor. In still other embodiments, the treatment is a surgery or a radiation therapy, and at least one of the plurality of cancer gene is a neoepitope that is tumor-specific and patient-specific.
- In some embodiments, the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status. Optionally, the DNA sequence data is obtained from circulating free DNA. In other embodiments, the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA. Optionally, the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- Typically, the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease. Preferably, the neoepitope is tumor-specific and patient-specific. In some embodiments, the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between a plurality of splice variants of the cancer gene.
- In still another aspect of the inventive subject matter, the inventors contemplate a method of evaluating an effectiveness of a treatment for a cancer patient. In this method, blood is obtained from a patient having a cancer. From the blood, omics data for a plurality of cancer genes are obtained before and after the treatment. Preferably, the omics data include at least one of DNA sequence data, RNA sequence data, and RNA expression level data. From the omics data, at least two cancer gene scores corresponding to the omics data before and after the treatment, respectively, are generated, and the effectiveness of the treatment is provided based on the comparison of the at least two cancer gene scores. In some embodiments, the effectiveness of the treatment can be determined by a difference between the cancer gene score before and after the treatment. In such embodiments, it is preferred that the treatment is determined effective when the difference is higher than a predetermined threshold value.
- In some embodiments, the treatment is a drug, and at least one of the plurality of cancer gene is a predicted target of the drug. In other embodiments, the treatment is an immune therapy, and at least one of the plurality of cancer gene is a receptor of an immune cell or a ligand of the receptor. In still other embodiments, the treatment is a surgery or a radiation therapy, and at least one of the plurality of cancer gene is a neoepitope that is tumor-specific and patient-specific.
- In some embodiments, the DNA sequence data v selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status. Optionally, the DNA sequence data is obtained from circulating free DNA. In other embodiments, the RNA sequence data is selected from the group consisting of mRNA sequence data and splice variant data, and/or the RNA expression level data is selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA. Optionally, the RNA sequence data is obtained from the group consisting of circulating tumor RNA and circulating free RNA.
- Typically, the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease. Preferably, the neoepitope is tumor-specific and patient-specific. In some embodiments, the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene. In other embodiments, the score is calculated based on a type of a splice variant of the cancer gene or a ratio between a plurality of splice variants of the cancer gene.
- Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.
- The inventors discovered that the status and/or prognosis of a cancer can be more reliably determined in a less invasive and quick manner using a compound score that is generated based on multiple factors associated with the cancer. The inventors also discovered that the compound score can be used to reliably predict a likelihood of outcome of a cancer treatment, and further, effectiveness of a particular cancer treatment. Viewed from a different perspective, the inventors discovered that a compound score can be generated from the patient's omics data obtained from nucleic acids in the patient's blood. Typically the omics data include omics data of various cancer-related genes, which can be differentially weighed based on the type and timing of the sampling. The compound score can be a reliable indicator to determine cancer status and/or prognosis of a cancer, a likelihood of outcome of a cancer treatment. Further, the compound scores generated based on omics data obtained before and after a cancer treatment can be compared to determine the effectiveness of a cancer treatment.
- As used herein, the term “tumor” refers to, and is interchangeably used with one or more cancer cells, cancer tissues, malignant tumor cells, or malignant tumor tissue, that can be placed or found in one or more anatomical locations in a human body.
- It should be noted that the term “patient” as used herein includes both individuals that are diagnosed with a condition (e.g., cancer) as well as individuals undergoing examination and/or testing for the purpose of detecting or identifying a condition. Thus, a patient having a tumor refers to both individuals that are diagnosed with a cancer as well as individuals that are suspected to have a cancer.
- As used herein, the term “provide” or “providing” refers to and includes any acts of manufacturing, generating, placing, enabling to use, transferring, or making ready to use.
- The inventors contemplate that tumor cells and/or some immune cells interacting or surrounding the tumor cells release cell free DNA/RNA to the patient's bodily fluid, and thus may increase the quantity of the specific cell free DNA/RNA in the patient's bodily fluid as compared to a healthy individual. As used herein, the patient's bodily fluid includes, but is not limited to, blood, serum, plasma, mucus, cerebrospinal fluid, ascites fluid, saliva, and urine of the patient. Alternatively, it should be noted that various other bodily fluids are also deemed appropriate so long as cell free DNA/RNA is present in such fluids. The patient's bodily fluid may be fresh or preserved/frozen. Appropriate fluids include saliva, ascites fluid, spinal fluid, urine, etc., which may be fresh or preserved/frozen.
- The cell free RNA may include any types of DNA/RNA that are circulating in the bodily fluid of a person without being enclosed in a cell body or a nucleus. Most typically, the source of the cell free DNA/RNA is the tumor cells. However, it is also contemplated that the source of the cell free DNA/RNA is an immune cell (e.g., NK cells, T cells, macrophages, etc.). Thus, the cell free DNA/RNA can be circulating tumor DNA/RNA (ctDNA/RNA) and/or circulating free DNA/RNA (cf DNA/RNA, circulating nucleic acids that do not derive from a tumor). While not wishing to be bound by a particular theory, it is contemplated that release of cell free DNA/RNA originating from a tumor cell can be increased when the tumor cell interacts with an immune cell or when the tumor cells undergo cell death (e.g., necrosis, apoptosis, autophagy, etc.). Thus, in some embodiments, the cell free DNA/RNA may be enclosed in a vesicular structure (e.g., via exosomal release of cytoplasmic substances) so that it can be protected from nuclease (e.g., RNAase) activity in some type of bodily fluid. Yet, it is also contemplated that in other aspects, the cell free DNA/RNA is a naked DNA/RNA without being enclosed in any membranous structure, but may be in a stable form by itself or be stabilized via interaction with one or more non-nucleotide molecules (e.g., any RNA binding proteins, etc.).
- It is contemplated that the cell free DNA/RNA can be any type of DNA/RNA which can be released from either cancer cells or immune cell. Thus, the cell free DNA may include any whole or fragmented genomic DNA, or mitochondrial DNA, and the cell free RNA may include mRNA, tRNA, microRNA, small interfering RNA, long non-coding RNA (lncRNA). Most typically, the cell free DNA is a fragmented DNA typically with a length of at least 50 base pair (bp), 100 base pair (bp), 200 bp, 500 bp, or 1 kbp. Also, it is contemplated that the cell free RNA is a full length or a fragment of mRNA (e.g., at least 70% of full-length, at least 50% of full length, at least 30% of full length, etc.). While cell free DNA/RNA may include any type of DNA/RNA encoding any cellular, extracellular proteins or non-protein elements, it is preferred that at least some of cell free DNA/RNA encodes one or more cancer-related proteins, or inflammation-related proteins. For example, the cell free DNA/mRNA may be full-length or fragments of (or derived from the) cancer related genes including, but not limited to ABL1, ABL2, ACTB, ACVR1B, AKT1, AKT2, AKT3, ALK, AMER11, APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ASXL1, ATF1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, EMSY, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEA, CEBPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CYLD, DAXX, DDR2, DEPTOR, DICER1, DNMT3A, DOT1L, EGFR, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, EREG, ERG, ERRFIL ESR1, EWSR1, EZH2, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBXW7, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLI1, FLT1, FLT3, FLT4, FOLH1, FOXL2, FOXP1, FRS2, FUBP1, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GRIN2A, GRM3, GSK3B, H3F3A, HAVCR2, HGF, HMGB1, HMGB2, HMGB3, HNF1A, HRAS, HSD3B1, HSP90AA1, IDHL IDH2, IDO, IGF1R, IGF2, IKBKE, IKZF1, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, MYST3, KDM5A, KDM5C, KDM6A, KDR, KEAP, KEL, KIT, KLHL6, KLK3, MLL, MLL2, MLL3, KRAS, LAG3, LMO1, LRP1B, LYN, LZTR1, MAGI2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MITF, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MUC1, MUTYH, MYC, MYCL, MYCN, MYD88, MYH, NF1, NF2, NFE2L2, NFKB1A, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NSD1, NTRK1, NTRK2, NTRK3, NUP93, PAK3, PALB2, PARK2, PAX3, PAX, PBRM1, PDGFRA, PDCD1, PDCD1LG2, PDGFRB, PDK1, PGR, PIK3C2B, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPP2R1A, PREX2, PRKAR1A, PRKC1, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, QK1, RAC1, RAD50, RAD51, RAF 1, RANBP1, RARA, RB1, RBM10, RET, RICTOR, RIT1, RNF43, ROS1, RPTOR, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX10, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, STAG2, STAT3, STAT4, STK11, SUFU, SYK, T (BRACHYURY), TAF1, TBX3, TERC, TERT, TET2, TGFRB2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, WISP3, WT1, XPO1, ZBTB2, ZNF217, ZNF703, CD26, CD49F, CD44, CD49F, CD13, CD15, CD29, CD151, CD138, CD166, CD133, CD45, CD90, CD24, CD44, CD38, CD47, CD96, CD45, CD90, ABCB5, ABCG2, ALCAM, ALPHA-FETOPROTEIN, DLL1, DLL3, DLL4, ENDOGLIN, GJA1, OVASTACIN, AMACR, NESTIN, STRO-1, MICL, ALDH, BMI-1, GLI-2, CXCR1, CXCR2, CX3CR1, CX3CL1, CXCR4, PON1, TROP1, LGR5, MSI-1, C-MAF, TNFRSF7, TNFRSF16, SOX2, PODOPLANIN, L1CAM, HIF-2 ALPHA, TFRC, ERCC1, TUBB3, TOP1, TOP2A, TOP2B, ENOX2, TYMP, TYMS, FOLR1, GPNMB, PAPPA, GART, EBNA1, EBNA2, LMP1, BAGE, BAGE2, BCMA, C10ORF54, CD4, CD8, CD19, CD20, CD25, CD30, CD33, CD80, CD86, CD123, CD276, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, CXCR3, CXCR5, CXCR6, CTAG1B, CTAG2, CTAG1, CTAG4, CTAG5, CTAG6, CTAG9, CAGE1, GAGE1, GAGE2A, GAGE2B, GAGE2C, GAGE2D, GAGE2E, GAGE4, GAGE10, GAGE12D, GAGE12F, GAGE12J, GAGE13, HHLA2, ICOSLG, LAG1, MAGEA10, MAGEA12, MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEA4, MAGEA5, MAGEA6, MAGEA7, MAGEA8, MAGEA9, MAGEB1, MAGEB2, MAGEB3, MAGEB4, MAGEB6, MAGEB10, MAGEB16, MAGEB18, MAGEC1, MAGEC2, MAGEC3, MAGED1, MAGED2, MAGED4, MAGED4B, MAGEE1, MAGEE2, MAGEF1, MAGEH1, MAGEL2, NCR3LG1, SLAMF7, SPAG1, SPAG4, SPAG5, SPAG6, SPAG7, SPAG8, SPAG9, SPAG11A, SPAG11B, SPAG16, SPAG17, VTCN1, XAGE1D, XAGE2, XAGE3, XAGE5, XCL1, XCL2, and XCR1. Of course, it should be appreciated that the above genes may be wild type or mutated versions, including missense or nonsense mutations, insertions, deletions, fusions, and/or translocations, all of which may or may not cause formation of full-length mRNA when transcribed.
- For another example, some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of inflammation-related proteins, including, but not limited to, HMGB1, HMGB2, HMGB3, MUC1, VWF, MMP, CRP, PBEF1, TNF-α, TGF-β, PDGFA, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, PDGF, and hTERT, and in yet another example, the cell free mRNA encoded a full length or a fragment of HMGB1.
- For still another example, some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of DNA repair-related proteins or RNA repair-related proteins. Table 1 provides an exemplary collection of predominant RNA repair genes and their associated repair pathways contemplated herein, but it should be recognized that numerous other genes associated with DNA repair and repair pathways are also expressly contemplated herein, and Tables 2 and 3 illustrate further exemplary genes for analysis and their associated function in DNA repair.
-
TABLE 1 Repair mechanism Predominant DNA Repair genes Base excision DNA glycosylase, APE1, XRCC1, PNKP, repair (BER) Tdp1, APTX, DNA polymerase β, FEN1, DNA polymerase δ or ϵ, PCNA-RFC, PARP Mismatch MutSα (MSH2-MSH6), MutSβ (MSH2- repair (MMR) MSH3), MutLα (MLH1-PMS2), MutLβ (MLH1-PMS2), MutLγ (MLH1-MLH3), Exo1, PCNA-RFC Nucleotide XPC-Rad23B-CEN2, UV-DDB (DDB1-XPE), excision repair CSA, CSB, TFIIH, XPB, XPD, XPA, RPA, (NER) XPG, ERCC1- XPF, DNA polymerase δ or ϵ Homologous Mre11-Rad50-Nbs1, CtIP, RPA, Rad51, recombination Rad52, BRCA1, BRCA2, Exo1, BLM-TopIIIα, (HR) GEN1-Yen1, Slx1- Slx4, Mus81/Eme1 Non-homologous Ku70-Ku80, DNA-PKc, XRCC4-DNA ligase end-joining IV, XLF (NHEJ) -
TABLE 2 Gene name Accession (synonyms) Activity number Base excision repair (BER) DNA glycosylases: major altered base released UNG U excision NM_003362 SMUG1 U excision NM_014311 MBD4 U or T opposite G at CpG sequences NM_003925 TDG U, T or ethenoC opposite G NM_003211 OGG1 8-oxoG opposite C NM_002542 MYH A opposite 8-oxoG NM_012222 NTH1 Ring-saturated or fragmented NM_002528 pyrimidines MPG 3-meA, ethenoA, hypoxanthine NM_002434 Other BER factors APE1 (HAP1, AP endonuclease NM_001641 APEX, REF1) APE2 (APEXL2) AP endonuclease NM_014481 LIG3 Main ligation function NM_013975 XRCC1 Main ligation function NM_006297 Poly(ADP-ribose) polymerase (PARP) enzymes ADPRT Protects strand interruptions NM_001618 ADPRTL2 PARP-like enzyme NM_005485 ADPRTL3 PARP-like enzyme AF085734 Direct reversal of damage MGMT O6-meG alkyltransferase NM_002412 Mismatch excision repair (MMR) MSH2 Mismatch and loop recognition NM_000251 MSH3 Mismatch and loop recognition NM_002439 MSH6 Mismatch recognition NM_000179 MSH4 MutS homolog specialized for meiosis NM_002440 MSH5 MutS homolog specialized for meiosis NM_002441 PMS1 Mitochondrial MutL homolog NM_000534 MLH1 MutL homolog NM_000249 PMS2 MutL homolog NM_000535 MLH3 MutL homolog of unknown function NM_014381 PMS2L3 MutL homolog of unknown function D38437 PMS2L4 MutL homolog of unknown function D38438 Nucleotide excision repair (NER) XPC Binds damaged DNA as complex NM_004628 RAD23B (HR23B) Binds damaged DNA as complex NM_002874 CETN2 Binds damaged DNA as complex NM_004344 RAD23A (HR23A) Substitutes for HR23B NM_005053 XPA Binds damaged DNA in preincision NM_000380 complex RPA1 Binds DNA in preincision complex NM_002945 RPA2 Binds DNA in preincision complex NM_002946 RPA3 Binds DNA in preincision complex NM_002947 TFIIH Catalyzes unwinding in preincision complex XPB (ERCC3) 3′ to 5′ DNA helicase NM_000122 XPD (ERCC2) 5′ to 3′ DNA helicase X52221 GTF2H1 Core TFIIH subunit p62 NM_005316 GTF2H2 Core TFIIH subunit p44 NM_001515 GTF2H3 Core TFIIH subunit p34 NM_001516 GTF2H4 Core TFIIH subunit p52 NM_001517 CDK7 Kinase subunit of TFIIH NM_001799 CCNH Kinase subunit of TFIIH NM_001239 MNAT1 Kinase subunit of TFIIH NM_002431 XPG (ERCC5) 3′ incision NM_000123 ERCC1 5′ incision subunit NM_001983 XPF (ERCC4) 5′ incision subunit NM_005236 LIG1 DNA joining NM_000234 NER-related CSA (CKN1) Cockayne syndrome; needed for NM_000082 transcription-coupled NER CSB (ERCC6) Cockayne syndrome; needed for NM_000124 transcription-coupled NER XAB2 (HCNP) Cockayne syndrome; needed for NM_020196 transcription-coupled NER DDB1 Complex defective in XP group E NM_001923 DDB2 Mutated in XP group E NM_000107 MMS19 Transcription and NER AW852889 Homologous recombination RAD51 Homologous pairing NM_002875 RAD51L1 Rad51 homolog U84138 (RAD51B) RAD51C Rad51 homolog NM_002876 RAD51L3 Rad51 homolog NM_002878 (RAD51D) DMC1 Rad51 homolog, meiosis NM_007068 XRCC2 DNA break and cross-link repair NM_005431 XRCC3 DNA break and cross-link repair NM_005432 RAD52 Accessory factor for recombination NM_002879 RAD54L Accessory factor for recombination NM_003579 RAD54B Accessory factor for recombination NM_012415 BRCA1 Accessory factor for transcription NM_007295 and recombination BRCA2 Cooperation with RAD51, essential NM_000059 function RAD50 ATPase in complex with MRE11A, NM_005732 NBS1 MRE11A 3′ exonuclease NM_005590 NBS1 Mutated in Nijmegen breakage NM_002485 syndrome Nonhomologous end-joining Ku70 (G22P1) DNA end binding NM_001469 Ku80 (XRCC5) DNA end binding M30938 PRKDC DNA-dependent protein kinase NM_006904 catalytic subunit LIG4 Nonhomologous end-joining NM_002312 XRCC4 Nonhomologous end-joining NM_003401 Sanitization of nucleotide pools MTH1 (NUDT1) 8-oxoGTPase NM_002452 DUT dUTPase NM_001948 DNA polymerases (catalytic subunits) POLB BER in nuclear DNA NM_002690 POLG BER in mitochondrial DNA NM_002693 POLD1 NER and MMR NM_002691 POLE1 NER and MMR NM_006231 PCNA Sliding clamp for pol delta and pol NM_002592 epsilon REV3L (POLZ) DNA pol zeta catalytic subunit, NM_002912 essential function REV7 (MAD2L2) DNA pol zeta subunit NM_006341 REV1 dCMP transferase NM_016316 POLH XP variant NM_006502 POLI (RAD30B) Lesion bypass NM_007195 POLQ DNA cross-link repair NM_006596 DINB1 (POLK) Lesion bypass NM_016218 POLL Meiotic function NM_013274 POLM Presumed specialized lymphoid NM_013284 function TRF4-1 Sister-chromatid cohesion AF089896 TRF4-2 Sister-chromatid cohesion AF089897 Editing and processing nucleases FEN1 (DNase IV) 5′ nuclease NM_004111 TREX1 (DNase III) 3′ exonuclease NM_007248 TREX2 3′ exonuclease NM_007205 EX01 (HEX1) 5′ exonuclease NM_003686 SPO11 endonuclease NM_012444 Rad6 pathway UBE2A (RAD6A) Ubiquitin-conjugating enzyme NM_003336 UBE2B (RAD6B) Ubiquitin-conjugating enzyme NM_003337 RAD18 Assists repair or replication of AB035274 damaged DNA UBE2VE (MMS2) Ubiquitin-conjugating complex AF049140 UBE2N (UBC13, Ubiquitin-conjugating complex NM_003348 BTG1) Genes defective in diseases associated with sensitivity to DNA damaging agents BLM Bloom syndrome helicase NM_000057 WRN Werner syndrome helicase/3′- NM_000553 exonuclease RECQL4 Rothmund-Thompson syndrome NM_004260 ATM Ataxia telangiectasia NM_000051 Fanconi anemia FANCA Involved in tolerance or repair NM_000135 of DNA cross-links FANCB Involved in tolerance or repair N/A of DNA cross-links FANCC Involved in tolerance or repair NM_000136 of DNA cross-links FANCD Involved in tolerance or repair N/A of DNA cross-links FANCE Involved in tolerance or repair NM_021922 of DNA cross-links FANCF Involved in tolerance or repair AF181994 of DNA cross-links FANCG (XRCC9) Involved in tolerance or repair NM_004629 of DNA cross-links Other identified genes with a suspected DNA repair function SNM1 (PS02) DNA cross-link repair D42045 SNM1B Related to SNM1 AL137856 SNMIC Related to SNM1 AA315885 RPA4 Similar to RPA2 NM_013347 ABH (ALKB) Resistance to alkylation damage X91992 PNKP Converts some DNA breaks to NM_007254 ligatable ends Other conserved DNA damage response genes ATR ATM-and PI-3K-like essential kinase NM_001184 RADI (S. pombe) PCNA-like DNA damage sensor NM_002853 homolog RAD9 (S. pombe) PCNA-like DNA damage sensor NM_004584 homolog HUS1 (S. pombe) PCNA-like DNA damage sensor NM_004507 homolog RAD17 (RAD24) RFC-like DNA damage sensor NM_002873 TP53BP1 BRCT protein NM_005657 CHEK1 Effector kinase NM_001274 CHK2 (Rad53) Effector kinase NM_007194 -
TABLE 3 Gene Name Gene Title Biological Activity RFC2 replication factor DNA replication C (activator 1) 2, 40 kDa XRCC6 X-ray repair DNA ligation///DNA repair///double-strand complementing break repair via nonhomologous end- defective repair joining///DNA recombination///positive in Chinese regulation of transcription, DNA- hamster dependent///double-strand break cells 6 (Ku repair via nonhomologous autoantigen, end-joining///response to DNA damage 70 kDa) stimulus///DNA recombination APOBEC apolipoprotein B For all of APOBEC1, APOBEC2, mRNA editing APOBEC3A-H, and APOBEC4, cytidine enzyme, catalytic deaminases. polypeptide-like POLD2 polymerase DNA replication///DNA replication (DNA directed), delta 2, regulatory sub- unit 50 kDa PCNA proliferating cell regulation of progression through cell nuclear antigen cycle///DNA replication///regulation of DNA replication///DNA repair///cell proliferation///phosphoinositide-mediated signaling///DNA replication RPA1 replication DNA-dependent DNA replication///DNA protein A1, repair///DNA recombination///DNA 70 kDa replication RPA1 replication DNA-dependent DNA replication///DNA protein A1, repair///DNA recombination/// 70 kDa DNA replication RPA2 replication DNA replication///DNA-dependent DNA protein A2, replication 32 kDa ERCC3 excision repair DNA topological change/// cross- transcription-coupled nucleotide- complementing excision repair///transcription/// rodent regulation of transcription, repair deficiency, DNA-dependent/// complementation transcription from RNA polymerase group 3 II promoter///induction of apoptosis/// (xeroderma sensory perception of sound/// pigmentosum DNA repair///nucleotide-excision group B repair///response to DNA damage complementing) stimulus///DNA repair UNG uracil-DNA carbohydrate metabolism///DNA glycosylase repair///base-excision repair/// response to DNA damage stimulus///DNA repair///DNA repair ERCC5 excision repair transcription-coupled nucleotide- cross- excision repair///nucleotide-excision complementing repair///sensory perception of rodent sound///DNA repair///response to DNA repair deficiency, damage stimulus///nucleotide- complementation excision repair group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome)) MLH1 mutL homolog mismatch repair///cell cycle///negative 1, colon cancer, regulation of progression through cell nonpolyposis cycle///DNA repair///mismatch repair/// type 2 (E. coli) response to DNA damage stimulus LIG1 ligase I, DNA, DNA replication///DNA repair///DNA ATP-dependent recombination///cell cycle/// morphogenesis///cell division///DNA repair///response to DNA damage stimulus///DNA metabolism NBN nibrin DNA damage checkpoint///cell cycle checkpoint///double-strand break repair NBN nibrin DNA damage checkpoint///cell cycle checkpoint///double-strand break repair NBN nibrin DNA damage checkpoint///cell cycle checkpoint///double-strand break repair MSH6 mutS homolog 6 mismatch repair///DNA metabolism///DNA (E. coli) repair///mismatch repair///response to DNA damage stimulus POLD4 polymerase DNA replication///DNA replication (DNA-directed), delta 4 RFC5 replication DNA replication///DNA repair///DNA factor replication C (activator 1) 5, 36.5 kDa RFC5 replication factor DNA replication///DNA repair///DNA C (activator 1) 5, replication 36.5 kDa DDB2/// damage-specific nucleotide-excision repair///regulation of LHX3 DNA binding transcription, DNA-dependent///organ protein 2, 48 morphogenesis///DNA repair///response to kDa///LIM DNA damage stimulus///DNA repair/// homeobox 3 transcription///regulation of transcription POLD1 polymerase DNA replication///DNA repair///response (DNA directed), to UV///DNA replication delta 1, catalytic subunit 125 kDa FANCG Fanconi anemia, cell cycle checkpoint///DNA repair///DNA complementation repair///response to DNA damage group G stimulus///regulation of progression through cell cycle POLB polymerase DNA-dependent DNA replication///DNA (DNA directed), repair///DNA replication///DNA repair/// beta response to DNA damage stimulus XRCC1 X-ray repair single strand break repair complementing defectivere pair in Chinese hamster cells 1 MPG N-methylpurine- base-excision repair///DNA dealkylation/// DNA DNA repair///base-excision repair/// glycosylase response to DNA damage stimulus RFC2 replication factor DNA replication C (activator 1) 2, 40 kDa ERCC1 excision repair nucleotide-excision repair/// cross- morphogenesis///nucleotide-excision complementing repair///DNA repair///response to DNA rodent repair damage stimulus deficiency, complementation group 1 (includes overlapping antisense sequence) TDG thymine-DNA carbohydrate metabolism///base-excision glycosylase repair///DNA repair///response to DNA damage stimulus TDG thymine-DNA carbohydrate metabolism///base-excision glycosylase repair///DNA repair///response to DNA damage stimulus FANCA Fanconi anemia, DNA repair///protein complex assembly/// complementation DNA repair///response to DNA damage group A/// stimulus Fanconi anemia, complementation group A RFC4 replication factor DNA replication///DNA strand elongation/// C (activator 1) DNA repair///phosphoinositide-mediated 4, 37 kDa signaling///DNA replication RFC3 replication factor DNA replication///DNA strand elongation C (activator 1) 3, 38 kDa RFC3 replication factor DNA replication///DNA strand elongation C (activator 1) 3, 38 kDa APEX2 APEX nuclease DNA repair///response to DNA damage (apurinic/ stimulus apyrimidinic endonuclease) 2 RAD1 RAD1 homolog DNA repair///cell cycle checkpoint///cell (S. pombe) cycle checkpoint///DNA damage check- point///DNA repair///response to DNA damage stimulus///meiotic prophase I RAD1 RAD1 homolog DNA repair///cell cycle checkpoint/// (S. pombe) cell cycle checkpoint///DNA damage checkpoint///DNA repair///response to DNA damage stimulus///meiotic prophase I BRCA1 breast cancer 1, regulation of transcription from RNA early onset polymerase II promoter///regulation of transcription from RNA polymerase III promoter///DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator///cell cycle///protein ubiquitination///androgen receptor signaling pathway///regulation of cell proliferation///regulation of apoptosis/// positive regulation of DNA repair/// negative regulation of progression through cell cycle///positive regulation of transcription, DNA-dependent/// negative regulation of centriole replication///DNA damage response, signal transduction resulting in induction of apoptosis///DNA repair///response to DNA damage stimulus///protein ubiquitination///DNA repair///regulation of DNA repair///apoptosis///response to DNA damage stimulus EXO1 exonuclease 1 DNA repair///DNA repair/// mismatch repair///DNA recombination FEN1 flap structure- DNA replication///double-strand break specific repair///UV protection///phosphoinositide- endonuclease 1 mediated signaling///DNA repair///DNA replication///DNA repair///DNA repair FEN1 flap structure- DNA replication///double-strand break specific repair///UV protection///phosphoinositide- endonuclease 1 mediated signaling///DNA repair///DNA replication///DNA repair///DNA repair MLH3 mutL homolog 3 mismatch repair///meiotic recombination/// (E. coli) DNA repair///mismatch repair///response to DNA damage stimulus///mismatch repair MGMT O-6-methyl- DNA ligation///DNA repair///response to guanine-DNA DNA damage stimulus methyltransferase RAD51 RAD51 homolog double-strand break repair via homologous (RecA homolog, recombination///DNA unwinding during E. coli) replication///DNA repair///mitotic (S. cerevisiae) recombination///meiosis///meiotic recombination///positive regulation of DNA ligation///protein homooligomerization/// response to DNA damage stimulus///DNA metabolism///DNA repair///response to DNA damage stimulus///DNA repair/// DNA recombination///meiotic recombination///double-strand break repair via homologous recombination///DNA unwinding during replication RAD51 RAD51 homolog double-strand break repair via homologous (RecA recombination///DNA unwinding during homolog, E. coli) replication///DNA repair///mitotic (S. cerevisiae) recombination///meiosis///meiotic recombination///positive regulation of DNA ligation///protein homooligomerization/// response to DNA damage stimulus///DNA metabolism///DNA repair///response to DNA damage stimulus///DNA repair///DNA recombination///meiotic recombination/// double-strand break repair via homologous recombination///DNA unwinding during replication XRCC4 X-ray repair DNA repair///double-strand break repair/// complementing DNA recombination///DNA defective repair in recombination///response to DNA damage Chinese hamster stimulus cells 4 XRCC4 X-ray repair DNA repair///double-strand break repair/// complementing DNA recombination///DNA defective repair in recombination///response to DNA Chinese hamster damage stimulus cells 4 RECQL RecQ protein- DNA repair///DNA metabolism like (DNA helicase Q1-like) ERCC8 excision repair DNA repair///transcription///regulation of cross- transcription, DNA-dependent///sensory complementing perception of sound///transcription- rodent repair coupled nucleotide-excision repair deficiency, complementation group 8 FANCC Fanconi anemia, DNA repair///DNA repair///protein complementation complex assembly///response to DNA group C damage stimulus OGG1 8-oxoguanine carbohydrate metabolism///base-excision DNA repair///DNA repair///base-excision glycosylase repair///response to DNA damage stimulus///DNA repair MRE11A MRE11 meiotic regulation of mitotic recombination/// recombination double-strand break repair via 11 homolog A nonhomologous end- (S. cerevisiae) joining///telomerase-dependent telomere maintenance///meiosis///meiotic recombination///DNA metabolism/// DNA repair///double-strand break repair/// response to DNA damage stimulus/// DNA repair///double-strand break repair/// DNA recombination RAD52 RAD52 homolog double-strand break repair///mitotic (S. cerevisiae) recombination///meiotic recombination/// DNA repair///DNA recombination/// response to DNA damage stimulus WRN Werner syndrome DNA metabolism///aging XPA xeroderma nucleotide-excision repair///DNA repair/// pigmentosum, response to DNA damage stimulus///DNA complementation repair///nucleotide-excision repair group A BLM Bloom syndrome DNA replication///DNA repair///DNA recombination///antimicrobial humoral response (sensu Vertebrata)///DNA metabolism///DNA replication OGG1 8-oxoguanine carbohydrate metabolism///base-excision DNA repair///DNA repair///base-excision glycosylase repair///response to DNA damage stimulus///DNA repair MSH3 mutS homolog 3 mismatch repair///DNA metabolism///DNA (E. coli) repair///mismatch repair///response to DNA damage stimulus POLE2 polymerase (DNA DNA replication///DNA repair///DNA directed), epsilon replication 2 (p59 subunit) RAD51C RAD51 homolog DNA repair///DNA recombination///DNA C (S. cerevisiae) metabolism///DNA repair///DNA recombination///response to DNA damage stimulus LIG4 ligase IV, DNA, single strand break repair///DNA ATP-dependent replication///DNA recombination///cell cycle///cell division///DNA repair/// response to DNA damage stimulus ERCC6 excision repair DNA repair///transcription///regulation of cross- transcription, DNA-dependent/// complementing transcription from RNA rodent repair polymerase II promoter///sensory deficiency, perception of sound complementation group 6 LIG3 ligase III, DNA, DNA replication///DNA repair///cell cycle/// ATP-dependent meiotic recombination///spermatogenesis/// cell division///DNA repair/// DNA recombination///response to DNA damage stimulus RAD17 RAD17 homolog DNA replication///DNA repair///cell cycle/// (S. pombe) response to DNA damage stimulus XRCC2 X-ray repair DNA repair///DNA recombination/// complementing meiosis///DNA metabolism///DNA repair/// defective repair in response to DNA damage stimulus Chinese hamster cells 2 MUTYH mutY homolog carbohydrate metabolism///base-excision (E. coli) repair///mismatch repair///cell cycle/// negative regulation of progression through cell cycle///DNA repair///response to DNA damage stimulus///DNA repair RFC1 replication factor DNA-dependent DNA replication/// C (activator 1) 1, transcription///regulation of transcription, 145 kDa/// DNA-dependent///telomerase-dependent replication factor telomere maintenance///DNA C (activator 1) 1, replication///DNA repair 145 kDa RFC1 replication factor DNA-dependent DNA replication/// C (activator 1) 1, transcription///regulation of transcription, 145 kDa DNA-dependent///telomerase- dependent telomere maintenance/// DNA replication///DNA repair BRCA2 breast cancer 2, regulation of progression through cell early onset cycle///double-strand break repair via homologous recombination///DNA repair///establishment and/or maintenance of chromatin architecture/// chromatin remodeling///regulation of S phase of mitotic cell cycle///mitotic checkpoint///regulation of transcription///response to DNA damage stimulus RAD50 RAD50 homolog regulation of mitotic recombination/// (S. cerevisiae) double-strand break repair///telomerase- dependent telomere maintenance/// cell cycle///meiosis///meiotic recombination///chromosome organization and biogenesis///telomere maintenance///DNA repair///response to DNA damage stimulus///DNA repair///DNA recombination DDB1 damage-specific nucleotide-excision repair///ubiquitin DNA binding cycle///DNA repair///response to DNA protein 1, damage stimulus///DNA repair 127 kDa XRCC5 X-ray repair double-strand break repair via complementing nonhomologous end-joining///DNA defective repair recombination///DNA repair/// in Chinese DNA recombination///response to hamster DNA damage stimulus///double-strand cells 5 (double- break repair strand-break rejoining; Ku autoantigen, 80 kDa) XRCC5 X-ray repair double-strand break repair via non- complementing homologous end-joining///DNA defective repair recombination///DNA repair/// in Chinese DNA recombination///response to DNA hamster damage stimulus///double-strand break cells 5 (double- repair strand-break rejoining; Ku autoantigen, 80 kDa) PARP1 poly (ADP-ribose) DNA repair///transcription from RNA polymerase polymerase II promoter///protein amino family, acid ADP-ribosylation///DNA member 1 metabolism///DNA repair///protein amino acid ADP-ribosylation/// response to DNA damage stimulus POLE3 polymerase (DNA DNA replication directed), epsilon 3 (p17 subunit) RFC1 replication factor DNA-dependent DNA replication/// C (activator 1) 1, transcription///regulation of transcription, 145 kDa DNA-dependent///telomerase- dependent telomere maintenance/// DNA replication///DNA repair RAD50 RAD50 homolog regulation of mitotic recombination/// (S. cerevisiae) double-strand break repair/// telomerase-dependent telomere maintenance///cell cycle///meiosis/// meiotic recombination///chromosome organization and biogenesis///telomere maintenance///DNA repair///response to DNA damage stimulus///DNA repair///DNA recombination XPC xeroderma nucleotide-excision repair///DNA repair/// pigmentosum, nucleotide-excision repair///response to complementation DNA damage stimulus///DNA repair group C MSH2 mutS homolog 2, mismatch repair///postreplication repair/// colon cancer, cell cycle///negative regulation nonpolyposis of progression through cell cycle/// type 1 (E. coli) DNA metabolism///DNA repair///mismatch repair///response to DNA damage stimulus///DNA repair RPA3 replication DNA replication///DNA repair///DNA protein A3, 14 kDa MBD4 methyl- replication base-excision repair///DNA CpG binding repair///response to DNA damage domain stimulus///DNA repair protein 4 MBD4 methyl-CpG base-excision repair///DNA repair/// binding domain response to DNA damage stimulus/// protein 4 DNA repair NTHL1 nth endonuclease carbohydrate metabolism///base-excision III-like 1 repair///nucleotide-excision repair, DNA (E. coli) incision, 5′-to lesion///DNA repair/// response to DNA damage stimulus PMS2/// PMS2 mismatch repair///cell cycle///negative PMS2CL postmeiotic regulation of progression through cell segregation cycle///DNA repair///mismatch increased 2 (S. repair///response to DNA damage cerevisiae)/// stimulus///mismatch repair PMS2-C terminal-like RAD51C RAD51 homolog DNA repair///DNA recombination///DNA C (S. cerevisiae) metabolism///DNA repair///DNA recombination///response to DNA damage stimulus UNG2 uracil-DNA regulation of progression through cell glycosylase 2 cycle///carbohydrate metabolism///base- excision repair///DNA repair///response to DNA damage stimulus APEX1 APEX nuclease base-excision repair///transcription from (multifunctional RNA polymerase II promoter///regulation DNA repair of DNA binding///DNA repair/// enzyme) 1 response to DNA damage stimulus ERCC4 excision repair nucleotide-excision repair///nucleotide- cross- excision repair///DNA metabolism///DNA complementing repair///response to DNA damage stimulus rodent repair deficiency, complementation group 4 RAD1 RAD1 homolog DNA repair///cell cycle checkpoint/// (S. pombe) cell cycle checkpoint///DNA damage checkpoint///DNA repair///response to DNA damage stimulus/// meiotic prophase I RECQL5 RecQ protein- DNA repair///DNA metabolism///DNA like 5 metabolism MSH5 mutS homolog 5 DNA metabolism///mismatch repair/// (E. coli) mismatch repair///meiosis///meiotic recombination///meiotic prophase II/// meiosis RECQL RecQ protein- DNA repair///DNA metabolism like (DNA helicase Q1-like) RAD52 RAD52 homolog double-strand break repair///mitotic (S. cerevisiae) recombination///meiotic recombination/// DNA repair///DNA recombination/// response to DNA damage stimulus XRCC4 X-ray repair DNA repair///double-strand break repair/// complementing DNA recombination///DNA defective repair recombination///response to DNA in Chinese damage stimulus hamster cells 4 XRCC4 X-ray repair DNA repair///double-strand break repair/// complementing DNA recombination///DNA defective repair in recombination///response to DNA Chinese hamster damage stimulus cells 4 RAD17 RAD17 homolog DNA replication///DNA repair///cell (S. pombe) cycle///response to DNA damage stimulus MSH3 mutS homolog mismatch repair/// 3 (E. coli) DNA metabolism///DNA repair/// mismatch repair///response to DNA damage stimulus MRE11A MRE11 meiotic regulation of mitotic recombination/// recombination 11 double-strand break repair via homolog A nonhomologous end-joining/// (S. cerevisiae) telomerase-dependent telomere maintenance///meiosis///meiotic recombination///DNA metabolism/// DNA repair///double-strand break repair///response to DNA damage stimulus///DNA repair///double-strand break repair///DNA recombination MSH6 mutS homolog 6 mismatch repair///DNA metabolism/// (E. coli) DNA repair///mismatch repair///response to DNA damage stimulus MSH6 mutS homolog 6 mismatch repair///DNA metabolism/// (E. coli) DNA repair///mismatch repair/// response to DNA damage stimulus RECQL5 RecQ protein- DNA repair///DNA metabolism///DNA like 5 metabolism BRCA1 breast cancer 1, regulation of transcription from RNA early onset polymerase II promoter///regulation of transcription from RNA polymerase III promoter///DNA damage response, signal transduction by p53 class mediator resultingi n transcription of p21 class mediator///cell cycle///protein ubiquitination///androgen receptor signaling pathway///regulation of cell proliferation///regulation of apoptosis///positive regulation of DNA repair///negative regulation of progression through cell cycle/// positive regulation of transcription, DNA-dependent///negative regulation of centriole replication///DNA damage response, signal transduction resulting in induction of apoptosis///DNA repair/// response to DNA damage stimulus/// protein ubiquitination///DNA repair/// regulation of DNA repair///apoptosis/// response to DNA damage stimulus RAD52 RAD52 homolog double-strand break repair///mitotic (S. cerevisiae) recombination///meiotic recombination/// DNA repair///DNA recombination/// response to DNA damage stimulus POLD3 polymerase DNA synthesis during DNA repair/// (DNA-directed), mismatch repair///DNA replication delta 3, accessory subunit MSH5 mutS homolog 5 DNA metabolism///mismatch repair/// (E. coli) mismatch repair///meiosis///meiotic recombination///meiotic prophase II///meiosis ERCC2 excision repair transcription-coupled nucleotide- cross- excision repair///transcription///regulation complementing of transcription, DNA-dependent/// rodent repair transcription from RNA polymerase II deficiency, promoter///induction of apoptosis/// complementation sensory perception of sound/// group 2 nucleobase, nucleoside, nucleotide (xeroderma and nucleic acid metabolism/// pigmentosum D) nucleotide-excision repair RECQL4 RecQ protein- DNA repair///development///DNA like 4 metabolism PMS1 PMS1 mismatch repair///regulation of postmeiotic transcription, DNA-dependent///cell segregation cycle///negative regulation increased 1 of progression through cell (S. cerevisiae) cycle///mismatch repair///DNA repair/// response to DNA damage stimulus ZFP276 zinc finger transcription///regulation of transcription, protein DNA-dependent 276 homolog (mouse) MBD4 methyl-CpG base-excision repair///DNA repair/// binding domain response to DNA damage stimulus/// protein 4 DNA repair MBD4 methyl-CpG base-excision repair///DNA repair/// binding domain response to DNA damage stimulus/// protein 4 DNA repair MLH3 mutL homolog 3 mismatch repair///meiotic recombination/// (E. coli) DNA repair///mismatch repair/// response to DNA damage stimulus/// mismatch repair FANCA Fanconi anemia, DNA repair///protein complex assembly/// complementation DNA repair///response to DNA damage group A stimulus POLE polymerase DNA replication///DNA repair///DNA (DNA directed), replication///response to DNA damage epsilon stimulus XRCC3 X-ray repair DNA repair///DNA recombination/// complementing DNA metabolism/// defective DNA repair///DNA recombination/// repair in Chinese response to DNA damage stimulus/// hamster cells 3 response to DNA damage stimulus MLH3 mutL homolog 3 mismatch repair///meiotic recombination/// (E. coli) DNA repair///mismatch repair/// response to DNA damage stimulus/// mismatch repair NBN nibrin DNA damage checkpoint///cell cycle checkpoint///double-strand break repair SMUG1 single-strand carbohydrate metabolism///DNA repair/// selective response to DNA damage stimulus monofunctional uracil DNA glycosylase FANCF Fanconi anemia, DNA repair///response to DNA damage complementation stimulus group F NEIL1 nei endonuclease carbohydrate metabolism///DNA repair/// VIII-like 1 response to DNA damage stimulus (E. coli) FANCE Fanconi anemia, DNA repair///response to DNA damage complementation stimulus group E MSH5 mutS homolog 5 DNA metabolism///mismatch repair/// (E. coli) mismatch repair///meiosis///meiotic recombination///meiotic prophase II/// meiosis RECQL5 RecQ protein- DNA repair///DNA metabolism///DNA like 5 metabolism - For still another example, some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of a gene not associated with a disease (e.g., housekeeping genes), including, but not limited to, those related to transcription factors (e.g., ATF1, ATF2, ATF4, ATF6, ATF7, ATFIP, BTF3, E2F4, ERH, HMGB1, ILF2, IER2, JUND, TCEB2, etc.), repressors (e.g., PUF60), RNA splicing (e.g., BAT1, HNRPD, HNRPK, PABPN1, SRSF3, etc.), translation factors (EIF1, EIF1AD, EIF1B, EIF2A, EIF2AK1, EIF2AK3, EIF2AK4, EIF2B2, EIF2B3, EIF2B4, EIF2S2, EIF3A, etc.), tRNA synthetases (e.g., AARS, CARS, DARS, FARS, GARS, HARS, IARS, KARS, MARS, etc.), RNA binding protein (e.g., ELAVL1, etc.), ribosomal proteins (e.g., RPL5, RPL8, RPL9, RPL10, RPL11, RPL14, RPL25, etc.), mitochondrial ribosomal proteins (e.g., MRPL9, MRPL1, MRPL10, MRPL11, MRPL12, MRPL13, MRPL14, etc.), RNA polymerase (e.g., POLR1C, POLR1D, POLR1E, POLR2A, POLR2B, POLR2C, POLR2D, POLR3C, etc.), protein processing (e.g., PPID, PPI3, PPIF, CANX, CAPN1, NACA, PFDN2, SNX2, SS41, SUM01, etc.), heat shock proteins (e.g., HSPA4, HSPA5, HSBP1, etc.), histone (e.g., HIST1HSBC, H1FX, etc.), cell cycle (e.g., ARHGAP35, RAB 10, RAB 11A, CCNY, CCNL, PPP1CA, RAD1, RAD17, etc.), carbohydrate metabolism (e.g., ALDOA, GSK3A, PGK1, PGAM5, etc.), lipid metabolism (e.g., HADHA), citric acid cycle (e.g., SDHA, SDHB, etc.), amino acid metabolism (e.g., COMT, etc.), NADH dehydrogenase (e.g., NDUFA2, etc.), cytochrome c oxidase (e.g., COX5B, COX8, COX11, etc.), ATPase (e.g. ATP2C1, ATP5F1, etc.), lysosome (e.g., CTSD, CSTB, LAMP1, etc.), proteasome (e.g., PSMA1, UBA1, etc.), cytoskeletal proteins (e.g., ANXA6, ARPC2, etc.), and organelle synthesis (e.g., BLOC1S1, AP2A1, etc.).
- In still another example, some cell free DNAs/mRNAs are fragments of or those encoding a full length or a fragment of a neoepitope specific to the tumor. With respect to neoepitope, it should be appreciated that neoepitopes can be characterized as random mutations in tumor cells that create unique and tumor specific antigens. Therefore, high-throughput genome sequencing should allow for rapid and specific identification of patient specific neoepitopes where the analysis also considers matched normal tissue of the same patient. In some embodiments, neoepitopes may be identified from a patient tumor in a first step by whole genome analysis of a tumor biopsy (or lymph biopsy or biopsy of a metastatic site) and matched normal tissue (i.e., non-diseased tissue from the same patient) via synchronous comparison of the so obtained omics information. While not limiting to the inventive subject matter, it is typically preferred that the data are patient matched tumor data (e.g., tumor versus same patient normal), and that the data format is in SAM, BAM, GAR, or VCF format. However, non-matched or matched versus other reference (e.g., prior same patient normal or prior same patient tumor, or homo statisticus) are also deemed suitable for use herein. Therefore, the omics data may be ‘fresh’ omics data or omics data that were obtained from a prior procedure (or even different patient). However, and especially where genomics ctDNA is analyzed, the neoepitope-coding sequence need not necessarily be expressed.
- In particularly preferred aspects, the nucleic acid encoding a neoepitope may encode a neoepitope that is also a suitable target for immune therapy. Therefore, neoepitopes can then be further filtered for a match to the patient's HLA type to thereby increase likelihood of antigen presentation of the neoepitope. Most preferably, and as further discussed below, such matching can be done in silico. Most typically, the patient-specific epitopes are unique to the patient, but may also in at least some cases include tumor type-specific neoepitopes (e.g., Her-2, PSA, brachyury) or cancer-associated neoepitopes (e.g., CEA, MUC-1, CYPB1).
- It is contemplated that cell free DNA/mRNA may present in modified forms or different isoforms. For example, the cell free DNA may be present in methylated or hydroxyl methylated, and the methylation level of some genes (e.g., GSTP1, p16, APC, etc.) may be a hallmark of specific types of cancer (e.g., colorectal cancer, etc.). The cell free mRNA may be present in a plurality of isoforms (e.g., splicing variants, etc.) that may be associated with different cell types and/or location. Preferably, different isoforms of mRNA may be a hallmark of specific tissues (e.g., brain, intestine, adipose tissue, muscle, etc.), or may be a hallmark of cancer (e.g., different isoform is present in the cancer cell compared to corresponding normal cell, or the ratio of different isoforms is different in the cancer cell compared to corresponding normal cell, etc.). For example, mRNA encoding HMGB1 are present in 18 different alternative splicing variants and 2 unspliced forms. Those isoforms are expected to express in different tissues/locations of the patient's body (e.g., isoform A is specific to prostate, isoform B is specific to brain, isoform C is specific to spleen, etc.). Thus, in these embodiments, identifying the isoforms of cell free mRNA in the patient's bodily fluid can provide information on the origin (e.g., cell type, tissue type, etc.) of the cell free mRNA.
- The inventors contemplate that the quantities and/or isoforms (or subtypes) or regulatory noncoding RNA (e.g., microRNA, small interfering RNA, long non-coding RNA (lncRNA)) can vary and fluctuate by presence of a tumor or immune response against the tumor. Without wishing to be bound by any specific theory, varied expression of regulatory noncoding RNA in a cancer patient's bodily fluid may due to genetic modification of the cancer cell (e.g., deletion, translocation of parts of a chromosome, etc.), and/or inflammations at the cancer tissue by immune system (e.g., regulation of miR-29 family by activation of interferon signaling and/or virus infection, etc.). Thus, in some embodiments, the cell free RNA can be a regulatory noncoding RNA that modulates expression (e.g., downregulates, silences, etc.) of mRNA encoding a cancer-related protein or an inflammation-related protein (e.g., HMGB1, HMGB2, HMGB3, MUC1, VWF, MMP, CRP, PBEF1, TNF-α, TGF-β, PDGFA, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, PDGF, hTERT, etc.).
- It is also contemplated that some cell free regulatory noncoding RNA may be present in a plurality of isoforms or members (e.g., members of miR-29 family, etc.) that may be associated with different cell types and/or location. Preferably, different isoforms or members of regulatory noncoding RNA may be a hallmark of specific tissues (e.g., brain, intestine, adipose tissue, muscle, etc.), or may be a hallmark of cancer (e.g., different isoform is present in the cancer cell compared to corresponding normal cell, or the ratio of different isoforms is different in the cancer cell compared to corresponding normal cell, etc.). For example, higher expression level of miR-155 in the bodily fluid can be associated with the presence of breast tumor, and the reduced expression level of miR-155 can be associated with reduced size of breast tumor. Thus, in these embodiments, identifying the isoforms of cell free regulatory noncoding RNA in the patient's bodily fluid can provide information on the origin (e.g., cell type, tissue type, etc.) of the cell free regulatory noncoding RNA.
- Any suitable methods to isolate and amplify cell free DNA/RNA are contemplated. Most typically, cell free DNA/RNA is isolated from a bodily fluid (e.g., whole blood) that is processed under a suitable conditions, including a condition that stabilizes cell free RNA. Preferably, both cell free DNA and RNA are isolated simultaneously from the same badge of the patient's bodily fluid. Yet, it is also contemplated that the bodily fluid sample can be divided into two or more smaller samples from which DNA or RNA can be isolated separately. Once separated from the non-nucleic acid components, cell free RNA are then quantified, preferably using real time, quantitative PCR or real time, quantitative RT-PCR.
- The bodily fluid of the patient can be obtained at any desired time point(s) depending on the purpose of the omics analysis. For example, the bodily fluid of the patient can be obtained before and/or after the patient is confirmed to have a tumor and/or periodically thereafter (e.g., every week, every month, etc.) in order to associate the cell free DNA/RNA data with the prognosis of the cancer. In some embodiments, the bodily fluid of the patient can be obtained from a patient before and after the cancer treatment (e.g., chemotherapy, radiotherapy, drug treatment, cancer immunotherapy, etc.). While it may vary depending on the type of treatments and/or the type of cancer, the bodily fluid of the patient can be obtained at least 24 hours, at least 3 days, at least 7 days after the cancer treatment. For more accurate comparison, the bodily fluid from the patient before the cancer treatment can be obtained less than 1 hour, less than 6 hours before, less than 24 hours before, less than a week before the beginning of the cancer treatment. In addition, a plurality of samples of the bodily fluid of the patient can be obtained during a period before and/or after the cancer treatment (e.g., once a day after 24 hours for 7 days, etc.).
- Additionally or alternatively, the bodily fluid of a healthy individual can be obtained to compare the sequence/modification of cell free DNA, and/or quantity/subtype expression of cell free RNA. As used herein, a healthy individual refers an individual without a tumor. Preferably, the healthy individual can be chosen among group of people shares characteristics with the patient (e.g., age, gender, ethnicity, diet, living environment, family history, etc.).
- Any suitable methods for isolating cell free DNA/RNA are contemplated. For example, in one exemplary method of DNA isolation, specimens were accepted as 10 ml of whole blood drawn into a test tube. Cell free DNA can be isolated from other from mono-nucleosomal and di-nucleosomal complexes using magnetic beads that can separate out cell free DNA at a size between 100-300 bps. For another example, in one exemplary method of RNA isolation, specimens were accepted as 10 ml of whole blood drawn into cell-free RNA BCT® tubes or cell-free DNA BCT® tubes containing RNA stabilizers, respectively. Advantageously, cell free RNA is stable in whole blood in the cell-free RNA BCT tubes for seven days while cell free RNA is stable in whole blood in the cell-free DNA BCT Tubes for fourteen days, allowing time for shipping of patient samples from world-wide locations without the degradation of cell free RNA. Moreover, it is generally preferred that the cell free RNA is isolated using RNA stabilization agents that will not or substantially not (e.g., equal or less than 1%, or equal or less than 0.1%, or equal or less than 0.01%, or equal or less than 0.001%) lyse blood cells. Viewed from a different perspective, the RNA stabilization reagents will not lead to a substantial increase (e.g., increase in total RNA no more than 10%, or no more than 5%, or no more than 2%, or no more than 1%) in RNA quantities in serum or plasma after the reagents are combined with blood. Likewise, these reagents will also preserve physical integrity of the cells in the blood to reduce or even eliminate release of cellular RNA found in blood cell. Such preservation may be in form of collected blood that may or may not have been separated. In less preferred aspects, contemplated reagents will stabilize cell free RNA in a collected tissue other than blood for at 2 days, more preferably at least 5 days, and most preferably at least 7 days. Of course, it should be recognized that numerous other collection modalities are also deemed appropriate, and that the cell free RNA can be at least partially purified or adsorbed to a solid phase to so increase stability prior to further processing.
- As will be readily appreciated, fractionation of plasma and extraction of cell free DNA/RNA can be done in numerous manners. In one exemplary preferred aspect, whole blood in 10 mL tubes is centrifuged to fractionate plasma at 1600 rcf for 20 minutes. The so obtained plasma is then separated and centrifuged at 16,000 rcf for 10 minutes to remove cell debris. Of course, various alternative centrifugal protocols are also deemed suitable so long as the centrifugation will not lead to substantial cell lysis (e.g., lysis of no more than 1%, or no more than 0.1%, or no more than 0.01%, or no more than 0.001% of all cells). Cell free RNA is extracted from 2 mL of plasma using Qiagen reagents. The extraction protocol was designed to remove potential contaminating blood cells, other impurities, and maintain stability of the nucleic acids during the extraction. All nucleic acids were kept in bar-coded matrix storage tubes, with DNA stored at −4° C. and RNA stored at −80° C. or reverse-transcribed to cDNA that is then stored at −4° C. Notably, so isolated cell free RNA can be frozen prior to further processing.
- Once cell free DNA/RNA is isolated, various types of omics data can be obtained using any suitable methods. DNA sequence data will not only include the presence or absence of a gene that is associated with cancer or inflammation, but also take into account mutation data where the gene is mutated, the copy number (e.g., to identify duplication, loss of allele or heterozygosity), and epigenetic status (e.g., methylation, histone phosphorylation, nucleosome positioning, etc.). With respect to RNA sequence data it should be noted that contemplated RNA sequence data include mRNA sequence data, splice variant data, polyadenylation information, etc. Moreover, it is generally preferred that the RNA sequence data also include a metric for the transcription strength (e.g., number of transcripts of a damage repair gene per million total transcripts, number of transcripts of a damage repair gene per total number of transcripts for all damage repair genes, number of transcripts of a damage repair gene per number of transcripts for actin or other household gene RNA, etc.), and for the transcript stability (e.g., a length of poly A tail, etc.).
- With respect to the transcription strength (expression level), transcription strength of the cell free RNA can be examined by quantifying the cell free RNA. Quantification of cell free RNA can be performed in numerous manners, however, expression of analytes is preferably measured by quantitative real-time RT-PCR of cell free RNA using primers specific for each gene. For example, amplification can be performed using an assay in a 10 μL reaction mix containing 2 μL cell free RNA, primers, and probe. mRNA of α-actin can be used as an internal control for the input level of cell free RNA. A standard curve of samples with known concentrations of each analyte was included in each PCR plate as well as positive and negative controls for each gene. Test samples were identified by scanning the 2D barcode on the matrix tubes containing the nucleic acids. Delta Ct (dCT) was calculated from the Ct value derived from quantitative PCR (qPCR) amplification for each analyte subtracted by the Ct value of actin for each individual patient's blood sample. Relative expression of patient specimens is calculated using a standard curve of delta Cts of serial dilutions of Universal Human Reference RNA set at a gene expression value of 10 (when the delta CTs were plotted against the log concentration of each analyte).
- Alternatively, where discovery or scanning for new mutations or changes in expression of a particular gene is desired, real time quantitative PCR may be replaced by RNAseq to so cover at least part of a patient transcriptome. Moreover, it should be appreciated that analysis can be performed static or over a time course with repeated sampling to obtain a dynamic picture without the need for biopsy of the tumor or a metastasis.
- Thus, omics data of cell free DNA/RNA preferably comprise a genomic data set that includes genomic sequence information. Most typically, the genomic sequence information comprises DNA sequence information of cell free DNA of the patient and optionally cell free DNA of a healthy individual. The sequence data sets may include unprocessed or processed data sets, and exemplary data sets include those having BAM format, SAM format, FASTQ format, or FASTA format. However, it is especially preferred that the data sets are provided in BAM format or as BAMBAM diff objects (see e.g., US2012/0059670A1 and US2012/0066001A1). Moreover, it should be noted that the data sets are reflective of the cell free DNA/RNA of the patient and of the healthy individual to so obtain patient and tumor specific information. Thus, genetic germ line alterations not giving rise to the diseased cells (e.g., silent mutation, SNP, etc.) can be excluded. Further, so obtained omics information can then be processed using pathway analysis (especially using PARADIGM) to identify any impact of any mutations on DNA repair pathways.
- Likewise, computational analysis of the sequence data may be performed in numerous manners. In most preferred methods, however, analysis is performed in silico by location-guided synchronous alignment of cell free DNA/RNA of the patient and a healthy individual as, for example, disclosed in US 2012/0059670A1 and US 2012/0066001A1 using BAM files and BAM servers. Such analysis advantageously reduces false positive data and significantly reduces demands on memory and computational resources.
- With respect to the analysis of cell free DNA/RNA of the patient and a healthy individual, numerous manners are deemed suitable for use herein so long as such methods will be able to generate a differential sequence object. However, it is especially preferred that the differential sequence object is generated by incremental synchronous alignment of BAM files representing genomic sequence information of the cell free DNA/RNA of the patient and a healthy individual. For example, particularly preferred methods include BAMBAM-based methods as described in US 2012/0059670 and US 2012/0066001.
- For calculation of a score, it should be appreciated that all data from ct/cf nucleic acids are deemed suitable for use herein and may therefore be specific to a particular tumor and/or patient and/or specific to a cancer. Furthermore, such data may be further normalized or otherwise preprocessed to adjust for age, treatment, gender, stage of disease, etc.
- For example, in one aspect of the inventive subject matter the inventors contemplate that a library or reference base for all cancer-related genes, inflammation-related genes, DNA repair-related genes, and/or other non-disease related housekeeping genes can be created using one or more omics data for each of those genes, and such library is particularly useful where the omics data are associated with one or more health parameter. Viewed from a different perspective, while traditional methods of determining cancer prognosis or predicting treatment outcome have been based on a few number of genes, such library can provide a tool to generate a large cross-sectional database for all cancer-related gene activity, inflammation-related gene activity, DNA repair gene activity and housekeeping gene activity (as a control). The large cross-sectional database can be a basis for generating a cancer matrix, based on which a prognosis of a cancer, a health status of the patient, a likelihood of outcome of treatment, an effectiveness of the treatment can be more reliably calculated.
- Of course, it should be appreciated that analyses presented herein may be performed over specific and diverse populations to so obtain reference values for the specific populations, such as across various health associated states (e.g., healthy, diagnosed with a specific disease and/or disease state, which may or may not be inherited, or which may or may not be associated with impaired DNA repair, inflammation-related autoimmunity, etc.), a specific age or age bracket, a specific ethnic group that may or may not be associated with frequent occurrence of specific type of cancer. Of course, populations may also be enlisted from databases with known omics information, and especially publically available omics information from cancer patients (e.g., TCGA, COSMIC, etc.) and proprietary databases from a large variety of individuals that may be healthy or diagnosed with a disease. Likewise, it should be appreciated that the population records may also be indexed over time for the same individual or group of individuals, which advantageously allows detection of shifts or changes in the genes and pathways associated with different types of cancers.
- In further particularly preferred aspects, it is contemplated that a cancer score can be established for one or more cancer-related genes, inflammation-related genes, a DNA-repair gene, a neoepitope, and a gene not associated with a disease and that the score may be reflective of or even prognostic for various types of cancer that are at least in part due to mutations in cancer-related genes and/or pathways. For example, especially suitable cancer scores may involve scores for one or more genes associated with one or more types of cancer (e.g., BRCA1, BRCA2, P53, etc.) relative to another gene that may or may not be associated with one type of cancer (e.g., housekeeping genes, etc.). In another example, contemplated cancer scores may involve scores for one or more genes associated with one or more types of one or more types of cancer (e.g., BRCA1, BRCA2, P53, etc.) relative to an overall mutation rate (e.g., mutation rate of the genes not associated with a disease, etc.) to so better identify cancer relevant mutations over ‘background’ mutations.
- Additionally, the omics data may be used to generate a general error status for an individual (or tumor within an individual), or to associate the number and/or type of alterations in cancer-related genes, inflammation-related genes, or a DNA-repair gene to identify a ‘tipping point’ for one or more gene mutations after which a general mutation rate skyrockets. For example, where a rate or number of mutations in ERCC1 and other DNA repair genes could have only minor systemic consequence, addition of further mutations to TP53 may result in a catastrophic increase in mutation rates. Thus, and viewed from a different perspective, mutations in the genes associated with DNA may be used to estimate the risk of occurrence for a DNA damage-based disease, and especially cancer and age-related diseases. In still further contemplated uses, so obtained omics information may be analyzed in one or more pathway analysis algorithms (e.g., PARADIGM) to so identify affected pathways and to so possibly adjust treatment where treatment employs DNA damaging agents. Pathway analysis algorithms may also be used to in silico modulate expression of one or more DNA repair genes, which may results in desirable or even unexpected in silico treatment outcomes, which may be translated into the clinic.
- With respect to calculation, the inventors contemplate that the cancer score is typically a compound score reflecting status of a plurality of genes. For example, the cancer score can be calculated by counting any mutations (e.g., deletion, missense, nonsense, etc.) of any cancer-related genes, inflammation-related genes, and DNA-repair genes with one or more mutations as having a positive value, counting any changes in methylation or other modifications in DNA of counting any cancer-related genes, DNA-repair genes, counting any upregulation or downregulation in expression levels of RNA of any cancer-related genes, inflammation-related genes, and DNA-repair genes, counting any presence of tumor-specific, patient specific neoepitopes, counting any changes or ratios in RNA isotypes (splice variants) of counting any cancer-related genes and DNA-repair genes, and counting any changes in length of poly A tail of any cancer-related genes, inflammation-related genes, and DNA-repair genes.
- The inventors further contemplate that each count may be weighed uniformly or biased, based on the significance of each count and then be assigned a value according to the weight of each count (e.g., each count corresponds to 1 point, some counts correspond to different scores such as 1 point, 3 points, 10 points, 100 points, etc.). Some mutations in some cancer related genes may be ‘leading indicators’ or triggers to activate other tumorigenesis mechanism or metastasis. Identification of such triggers may advantageously allow for early diagnosis or intervention of the cancer. Thus, for example, a mutation in a cancer-specific gene among cancer-related genes, inflammation-related genes, or DNA-repair genes may be weighed higher than other cancer-related genes or DNA-repair genes (e.g., at least 3 times, at least 5 times, at least 10 times, at least 100 times, etc.) and can be assigned to higher values accordingly. As used herein the cancer-specific gene refers any gene or mutation of the gene that is a known genetic disposition (e.g., significantly increase a susceptibility to the disease) of specific types of cancer (e.g., BRCA1 and BRCA2 for breast cancer and ovarian cancer, etc.). In another example, each gene in any cancer-related pathway or DNA-repair pathway may be differently weighed (e.g., most significant, significant, moderate, less significant, insignificant, etc.) and any mutation of a such gene that has any or no impact (e.g., adversely affect the pathway stream, etc.) on any cancer-related pathway or DNA-repair pathway may be weighed differently based on the significance of the impact. Thus, for example, gene A encoding a significant, unreplaceable protein A in a cancer pathway may be weighed heavier than another gene B encoding a redundant protein (replaceable with other proteins). Also, a nonsense mutation in gene A that results in nonfunctional protein may be weighed at least 3 times, at least 5 times, at least 10 times, at least 100 times than a silent mutation in gene A or a missense mutation which does not affect the function of protein A and can be assigned to higher values accordingly.
- In some embodiments, some countings may weigh equally or differently based on the significance of each counting and then be assigned to a negative value according to the weight of each counting (e.g., each counting corresponds to −1 point, some countings correspond to different scores such as −1 point, −3 points, −10 points, −100 points, etc.). For example, upregulation of mRNA of gene C, which can compensate the loss of function of gene A, can be assigned to a negative value (e.g., −10 points) such that it can compensate the positive value of mutation of gene A (e.g., +10 points).
- It is also contemplated that some countings may be differently weighed based on the degree of changes in expression level of some RNAs. For example, when the expression level of RNA “X” increases at least twice, at least 5 times, at least 10 times, at least 20 times, while other RNA expression level change is below 50% at best, then the increase of expression level of RNA “X” may be weighed at least 3 times, at least 5 times, at least 10 times, at least 100 times than other genes.
- Most typically, the cancer score is compound score that is a total sum of all values assigned to all counts. In some embodiments, the cancer score can be a total sum of all values assigned to all counts (all omics data). In other embodiments, the cancer score can be a total sum of a selected number of values assigned to some counts (e.g., corresponding to specific pathways, specific types of genes, specific groups of mechanisms, etc.). Thus, the cancer score increases as more cancer-related genes or DNA-repair genes possess one or more mutations. In some embodiments, each mutation and/or change may be counted separately such that cancer scores may further increase where one or more cancer-related genes or DNA-repair genes show multiple mutations in a single gene. In other embodiments, cancer score may further increase when such multiple mutations in a single gene may further affect the function of the cancer-related genes or DNA-repair genes such that the multiple mutations drive the cells more cancer-prone, or more cancerous, or drive the cancer microenvironment more immune-resistant, and so on.
- Alternatively or additionally, the cancer score can be presented as a trajectory with one or more counts as its vectors, where a few numbers of variables and/or factors dominantly govern in determination of cancer prognosis. Each of variables and/or factors can be presented as a vector, whose amplitude is corresponding to the point of each weighted counting, and the addition of those vectors provides a trajectory indicating the prognosis of the disease. Viewed form a different perspective, it should be appreciated that multiple analyses over time can be prepared for the same patient, and that changes over time (e.g., with or without treatment) may be assigned specific values that will yet again generate a time-dependent score. Such scores or changes over time may be classified and serve as leading indicator for treatment outcome, drug response, etc.
- Additionally, it is also contemplated that the cancer score can be calculated with health information other than cf/ct nucleic acid data obtained from the patient's blood. For example, the health information may include expression levels/concentrations of several types of cytokines (e.g., IL-2, TNF-α, etc.) related to tumorigenesis/inflammation/immune response against the tumor, hormone levels (e.g., estrogen, progesterone, growth hormone, etc.), blood sugar level, alanine transaminase level (for liver function), creatine level (for kidney function), blood pressure, types and quantity of tumor cell-secreted proteins (e.g., soluble ligands of immune cell receptor, etc.) or foreign antigenic proteins (e.g., for virus or bacterial infection, etc.).
- The inventors contemplated that the so obtained cancer score can be used to provide a diagnosis of cancer or risk of having or developing a cancer. In some embodiments, the calculated cancer score of a patient can be compared with an average cancer score of healthy individuals to determine the difference between two scores. Preferably, when the difference between two scores is above a threshold value, the patient may be diagnosed to have a tumor, or has a high risk to have a tumor. In other embodiments, the calculated cancer score of a patient can be compared with a predetermined threshold score. The predetermined threshold score can be a predetermined score, which may vary depending on patient's ethnicity, age, gender, or other health status. In other embodiments, the predetermined threshold score can a dynamic score that can be changed based on a previous cancer score and a diagnosis or treatment performed to the patient.
- The inventors also contemplate that the so obtained cancer score can be used to provide a prognosis of the cancer. For example, the cancer scores can be calculated based on omics data obtained in month 1, month 3, month 6, and month 12 after the patient got diagnosed with a first stage of lung cancer, and each cancer score can be compared with a predetermined threshold score corresponding to the month 1, 3, 6, and 12. The cancer scores are about 120% of the threshold score in month 1 and 3, and the cancer score is about 180% in month 6, and 230% of the threshold score month 12. Such progress indicates that the prognosis of the lung cancer of the patient is not optimistic if the progress is not intervened. In another example, the cancer score can be calculated by highly weighing the presence of neoepitopes that are tumor-specific and patient-specific. In this example, the cancer scores can be calculated based on omics data obtained in month 1, month 3, month 6, and month 12 after the patient got diagnosed with a first stage of lung cancer, and each cancer score is calculated by highly weighing the presence/appearance of new epitope that is tumor/tissue specific. The cancer scores are about 120% of the threshold score in month 1 and 3, and the cancer score is about 140% in month 6, and 230% of the threshold score month 12. Such progress indicates a possible metastasis of the tumor to another organ (releasing different type of neoepitope) or development of different type of tumor in the same organ (releasing different type of neoepitope).
- In a further example, the cancer scores can provide an indicator for treatment options. The treatment option may be a prophylactic treatment where the compound score is below the threshold value, indicating that the patient is unlikely to have a tumor for now or at least has low risk of developing a tumor. When the cancer score is above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a cancer-related gene A (e.g., over a threshold such as at least 10%, at least 20%, at least 30%, at least 50%, etc.), then the cancer score can be used to provide the treatment option that may use a drug inhibiting the activity of cancer-related gene A (e.g., a blocker of protein A, etc.). Similarly, when the cancer score is above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a gene encoding a receptor of an immune cell or a ligand of the receptor, then the cancer score can be used to provide the immunotherapy using the receptor or ligand of the immune cells. Also, when the cancer score is above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a specific neoepitope, then the cancer score can be used to provide the immunotherapy using the neoepitope as a bait or a surgery/a radiation therapy to physically remove local tumors. Also such cancer scores may be an indicative of likelihood of success for the treatment option. However, if the portion of the cancer score highly weighted was overexpression of a cancer-related gene A is below the threshold, then the treatment option using a drug inhibiting the activity of cancer-related gene A may be predicted less effective.
- Consequently, the patient can be treated with at least one of the treatment options based on the patient's cancer (compound) score. For example, above the threshold value and a majority portion of the cancer score highly weighted was overexpression of a specific neoepitope, the treatment option can be selected to include a recombinant virus (or yeast or bacteria) comprising a nucleic acid encoding the specific neoepitope. Then, the recombinant virus can be administered to the patient in a dose and schedule effective to treat the tumor and/or effective to reduce the cancer score of the patient for at least 10%, at least 20%, at least 30%, at least in 2 weeks, at least in 4 weeks, at least in 8 weeks, at least in 12 weeks after the administration or a series of administrations.
- It is also contemplated that the patient's cancer score can be compared with one or more other patients having same type of cancer and having a treatment history to provide a treatment option and predicted outcome. For example, where other patients' history indicates that the drug treatment is effective only when the cancer score is below 200 (as absolute score), or less than 180% of the healthy individual's score, and the patient's cancer score has been increasing from 140 to 160 for the last 2 weeks, a recommendation to proceed with drug treatment no later than 2 weeks can be provided based on the other patients' history and cancer scores.
- The calculated cancer score can also be an indicator of an effectiveness of a cancer treatment, especially when the omics data includes information of at least one or more genes encoding a target/indicator of the cancer treatment. For example, cancer scores can be calculated based on omics data obtained before the cancer treatment, 7 days after, 2 weeks, 1 month, and 6 months of the cancer treatment. The cancer score of 7 days after the treatment is 80% of the cancer score before the treatment, and the cancer score of 2 weeks and 1 month after the treatment is 50% of the cancer score before the treatment, and the cancer score of 6 months after the treatment is 150% of the cancer score before the treatment. Such progress indicates that the treatment was effective at least for a short term (e.g., up to 1 month), yet the effectiveness is decreased over time and may not effective at all in 6 months after the treatment. In some embodiments, the cancer scores before and after treatment can be compared with a predetermined threshold value to determine the effectiveness of the treatment. For example, if the cancer score is 200 before the treatment and 130 after the treatment where the threshold cancer score is 100, then the treatment can be determined “effective” as the cancer score drops below the threshold after the treatment. However, if the cancer score is 200 before the treatment and 160 after the treatment where the threshold cancer score is 150, then the treatment can be determined “not effective” as the cancer score stays above the threshold after the treatment even though the absolute value of the cancer score is decreased. Consequently, the inventors further contemplate that the patient continues with administering the treatment option (e.g., immune therapy, etc.) when the treatment can be determined “effective”, when the cancer score after the treatment is lower than the predetermined threshold, when the cancer score after the treatment is at most 5%, at most 10% higher than the predetermined threshold, or when the cancer score after the treatment is at least 5%, at least 10%, at least 15% lower than the predetermined threshold. s
- The inventors also contemplate that the effectives of some cancer treatments can be determined by analyzing omics data including foreign DNA/RNA originated from a carrier of the immune therapy (e.g., virus, bacteria, yeast, etc.). For example, where the virus is a carrier to deliver a recombinant nucleic acid encoding recombinant killer activation receptor (KAR), the level of cell free DNA/RNA of recombinant KAR in the patient blood can be an indicator of an effectiveness of infection of the virus.
- It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the scope of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms “comprises” and “comprising” should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise. Where the specification claims refers to at least one of something selected from the group consisting of A, B, C . . . and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.
Claims (17)
1. A method of evaluating an effectiveness of a treatment for a cancer patient, comprising:
obtaining blood from a patient having a cancer;
obtaining from the blood omics data of the cancer patient before and after the treatment for a plurality of cancer-related genes, wherein the omics data comprise at least one of DNA sequence data, RNA sequence data, and RNA expression level;
analyzing the omics data to generate first and second cancer gene scores, wherein the first and cancer gene scores correspond to the omics data before and after the treatment, respectively; and
providing the effectiveness of the treatment based on a comparison of the first and second cancer gene scores.
2. The method of claim 1 , wherein the plurality of cancer-related genes comprises at least one of a cancer-related gene, a cancer-specific gene, a DNA-repair gene, a neoepitope, and a gene not associated with a disease.
3. The method of claim 2 , wherein the neoepitope is tumor specific and patient specific.
4. The method of claim 1 , wherein the DNA sequence data are selected from the group consisting of mutation data, copy number data duplication, loss of heterozygosity data, and epigenetic status.
5. The method of claim 1 , wherein the RNA sequence data are selected from the group consisting of mRNA sequence data and splice variant data.
6. The method of claim 1 , wherein the RNA expression level data are selected from the group consisting of a quantity of RNA transcript and a quantity of a small noncoding RNA.
7. The method of claim 1 , wherein DNA sequence data are obtained from circulating free DNA.
8. The method of claim 1 , wherein the RNA sequence data are obtained from the group consisting of circulating tumor RNA and circulating free RNA.
9. The method of claim 4 , wherein the plurality of cancer-related genes includes a cancer-specific gene, and the score is calculated based on a presence or an absence of a mutation in the cancer-specific gene.
10. The method of claim 9 , wherein the presence of the mutation in the cancer-specific gene weighs more than the presence of the mutation in the cancer-related genes other than the cancer-specific gene.
11. The method of claim 5 , wherein the score is calculated based on a type of a splice variant of the cancer gene or a ratio between a plurality of splice variants of the cancer gene.
12. The method of claim 1 , wherein the treatment is a drug, and at least one of the plurality of cancer gene is a predicted target of the drug.
13. The method of claim 1 , wherein the treatment is an immune therapy, and at least one of the plurality of cancer gene is a receptor of an immune cell or a ligand of the receptor.
14. The method of claim 1 , wherein the treatment is a surgery or a radiation therapy, and at least one of the plurality of cancer gene is a neoepitope that is tumor-specific and patient-specific.
15. The method of claim 1 , wherein the effectiveness of the treatment is determined by comparing the cancer gene score after the treatment with a predetermined threshold value.
16. The method of claim 1 , wherein the effectiveness of the treatment is determined by a difference between the cancer gene score before and after the treatment.
17. The method of claim 16 , wherein the treatment is determined effective when the difference is higher than a predetermined threshold value.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/465,868 US20230420137A1 (en) | 2017-10-12 | 2023-09-12 | Cancer Score for Assessment and Response Prediction from Biological Fluids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762571414P | 2017-10-12 | 2017-10-12 | |
PCT/US2018/055481 WO2019075251A2 (en) | 2017-10-12 | 2018-10-11 | Cancer score for assessment and response prediction from biological fluids |
US202016754088A | 2020-04-06 | 2020-04-06 | |
US18/465,868 US20230420137A1 (en) | 2017-10-12 | 2023-09-12 | Cancer Score for Assessment and Response Prediction from Biological Fluids |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/055481 Division WO2019075251A2 (en) | 2017-10-12 | 2018-10-11 | Cancer score for assessment and response prediction from biological fluids |
US16/754,088 Division US11810672B2 (en) | 2017-10-12 | 2018-10-11 | Cancer score for assessment and response prediction from biological fluids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230420137A1 true US20230420137A1 (en) | 2023-12-28 |
Family
ID=66101142
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/754,088 Active 2039-09-14 US11810672B2 (en) | 2017-10-12 | 2018-10-11 | Cancer score for assessment and response prediction from biological fluids |
US18/465,868 Pending US20230420137A1 (en) | 2017-10-12 | 2023-09-12 | Cancer Score for Assessment and Response Prediction from Biological Fluids |
US18/474,797 Pending US20240021314A1 (en) | 2017-10-12 | 2023-09-26 | Cancer Score for Assessment and Response Prediction from Biological Fluids |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/754,088 Active 2039-09-14 US11810672B2 (en) | 2017-10-12 | 2018-10-11 | Cancer score for assessment and response prediction from biological fluids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/474,797 Pending US20240021314A1 (en) | 2017-10-12 | 2023-09-26 | Cancer Score for Assessment and Response Prediction from Biological Fluids |
Country Status (6)
Country | Link |
---|---|
US (3) | US11810672B2 (en) |
CN (1) | CN111213209A (en) |
AU (1) | AU2018348249A1 (en) |
CA (1) | CA3077221A1 (en) |
SG (1) | SG11202002711WA (en) |
WO (1) | WO2019075251A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111213209A (en) | 2017-10-12 | 2020-05-29 | 南托米克斯有限责任公司 | Cancer scoring and response prediction from assessment of biological fluids |
US11168356B2 (en) * | 2017-11-02 | 2021-11-09 | The Chinese University Of Hong Kong | Using nucleic acid size range for noninvasive cancer detection |
EP3977477A1 (en) * | 2019-05-24 | 2022-04-06 | Yeda Research and Development Co. Ltd | Method and system for predicting gestational diabetes |
JP7168270B2 (en) * | 2019-12-24 | 2022-11-09 | イーソリューションズ株式会社 | Health management system and health management method |
US20220042109A1 (en) * | 2020-08-06 | 2022-02-10 | Agendia NV | Methods of assessing breast cancer using circulating hormone receptor transcripts |
CN116917733A (en) * | 2020-12-17 | 2023-10-20 | 匹兹堡大学高等教育联邦体系 | Multiple-set of learning methods for precision medicine |
WO2023196390A1 (en) * | 2022-04-06 | 2023-10-12 | Foundation Medicine, Inc. | Aneuploidy biomarkers associated with response to anti-cancer therapies |
CN114959026A (en) * | 2022-04-15 | 2022-08-30 | 深圳市陆为生物技术有限公司 | Application of reagent for detecting gene in preparation of product for evaluating recurrence risk of breast cancer patient |
CN115132327B (en) * | 2022-05-25 | 2023-03-24 | 中国医学科学院肿瘤医院 | Microsatellite instability prediction system, construction method thereof, terminal equipment and medium |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2797645C (en) | 2010-05-25 | 2020-09-22 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
EP2721180A4 (en) * | 2011-06-16 | 2015-09-02 | Decode Genetics Ehf | Genetic variants for predicting risk of breast cancer |
US9422592B2 (en) | 2012-01-06 | 2016-08-23 | Viomics, Inc. | System and method of detecting RNAS altered by cancer in peripheral blood |
WO2013190089A1 (en) * | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
CN113337604A (en) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | Identification and use of circulating nucleic acid tumor markers |
ES2829415T3 (en) * | 2013-05-30 | 2021-05-31 | Genomic Health Inc | Gene expression profiling algorithm to calculate a recurrence score for a kidney cancer patient |
CN107002122B (en) * | 2014-07-25 | 2023-09-19 | 华盛顿大学 | Method for determining tissue and/or cell type leading to the production of cell-free DNA and method for identifying diseases or disorders using the same |
MA40737A (en) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY |
EP3384050A4 (en) | 2015-12-03 | 2019-07-31 | Alfred Health | Monitoring treatment or progression of myeloma |
US10982286B2 (en) | 2016-01-22 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine |
MX2019000733A (en) * | 2016-07-20 | 2019-05-02 | Biontech Rna Pharmaceuticals Gmbh | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy. |
WO2018231860A1 (en) * | 2017-06-12 | 2018-12-20 | Grail, Inc. | Alignment free filtering for identifying fusions |
CN111213209A (en) | 2017-10-12 | 2020-05-29 | 南托米克斯有限责任公司 | Cancer scoring and response prediction from assessment of biological fluids |
-
2018
- 2018-10-11 CN CN201880066565.6A patent/CN111213209A/en not_active Withdrawn
- 2018-10-11 WO PCT/US2018/055481 patent/WO2019075251A2/en active Application Filing
- 2018-10-11 SG SG11202002711WA patent/SG11202002711WA/en unknown
- 2018-10-11 AU AU2018348249A patent/AU2018348249A1/en not_active Withdrawn
- 2018-10-11 CA CA3077221A patent/CA3077221A1/en not_active Withdrawn
- 2018-10-11 US US16/754,088 patent/US11810672B2/en active Active
-
2023
- 2023-09-12 US US18/465,868 patent/US20230420137A1/en active Pending
- 2023-09-26 US US18/474,797 patent/US20240021314A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200335215A1 (en) | 2020-10-22 |
SG11202002711WA (en) | 2020-04-29 |
WO2019075251A2 (en) | 2019-04-18 |
US20240021314A1 (en) | 2024-01-18 |
US11810672B2 (en) | 2023-11-07 |
WO2019075251A3 (en) | 2019-07-25 |
CN111213209A (en) | 2020-05-29 |
AU2018348249A1 (en) | 2020-04-16 |
CA3077221A1 (en) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11810672B2 (en) | Cancer score for assessment and response prediction from biological fluids | |
US20200165685A1 (en) | Circulating rna for detection, prediction, and monitoring of cancer | |
US20180087114A1 (en) | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid | |
US20220290252A1 (en) | Method of isolating circulating nucleosomes | |
US20230323476A1 (en) | Targeted cell free nucleic acid analysis | |
US20190234955A1 (en) | Exosome-guided treatment of cancer | |
TW201918560A (en) | Circulating RNA for detection, prediction, and monitoring of cancer | |
US20200248267A1 (en) | TUMOR VS. MATCHED NORMAL cfRNA | |
US20200234790A1 (en) | Dna repair profiling and methods therefor | |
US20200385815A1 (en) | Using cfRNA for Diagnosing Minimal Residual Disease | |
US20230160881A1 (en) | HMGB1 RNA And Methods Therefor | |
WO2023284736A1 (en) | Biomarkers for colorectal cancer treatment | |
US20240105279A1 (en) | Methods and systems employing targeted next generation sequencing for classifying a tumor sample as having a level of homologous recombination deficiency similar to that associated with mutations in brca1 or brca2 genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |